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ABSTRACT 
Various manifestations of atherosclerotic cardiovascular disease are a common clinical 
problem affecting millions of people each year and the prevalence increases globally. This 
strengthens the incentives to improve the tools for primary and secondary prevention. 
Cystatin C is, besides its role as a marker of renal function, a promising biomarker of 
vascular damage and vascular disease, which might add value to risk prediction in 
cardiovascular burdened individuals as well as in persons free of cardiovascular disease. 
Atherosclerotic cardiovascular diseases are polygenic disorders, and disease development is 
a function of complex relationships between several environmental factors and multiple 
genetic variations. The relative impact of genes and environment on the variations in, 
biomarkers such as cystatin C and creatinine and on their association to cardiovascular 
disease (CVD), is not well-known and requires further studies. The overall aim of this thesis 
has been to study the relation between cystatin C and cardiovascular disease, to investigate 
if it may be used as a biomarker for atherosclerotic disease and if it could lead to earlier 
identification of patients at particularly high risk. In addition, we investigated the 
heritability of cystatin C and its relation to heritability of cardiovascular disease. Finally we 
studied the predictive value of cystatin C for incident CVD when controlled for genetic 
confounding in twin studies.  
Material and methods. This thesis is based on studies in two different study groups. The 
first consists of elderly men with peripheral arterial disease (PAD) (n103=) and matched 
controls (n=96) and the second is a population based cohort of elderly Swedish twins of 
both sexes (n=12313). Initially we performed a cross-sectional study in which we 
investigated differences in cystatin C-levels between PAD-patients and matched controls. 
We further studied the predictive value of cystatin C with regards to secondary 
cardiovascular events in the same group. In the twin study group we investigated the 
heritability of cystatin C and prevalent CVD using a structured equation model (SEM) 
followed by a genome-wide complex trait analysis (GCTA).  Finally the predictive ability 
of cystatin C for incident atherosclerotic cardiovascular disease (ASCVD) during a follow-
up of 71 month was studied in an adjusted Cox-regression model in twins free from CVD at 
baseline (n= 11402). Twin pairs discordant for incident ASCVD during follow up were 
identified and within-pair comparisons regarding cystatin C and creatinine levels were 
performed. 
Results. We observed that cystatin C-levels were higher in PAD patients compared to 
healthy controls even when corrected for differences in eGFR, IL-6 and CRP. In follow-up 
we could not establish cystatin C as a predictive marker of incident cardiovascular events in 
patients with manifest PAD, however we unexpectedly found a U-shaped relation between 
tertiles of cystatin C-concentration and outcome. Further we observed a higher heritability of 
cystatin C compared with previous studies, for which the GCTA analysis provided 
independent evidence. We also observed a significant genetic correlation between levels of 
cystatin C and CVD. Lastly we showed that cystatin C was a predictor for incident 
myocardial infarction (MI) and stroke. The association for stroke was higher than for MI, and 
that cystatin C remained a predictor for incident stroke after adjustment for genetic 
confounding. 
Conclusion. Cystatin C is associated to atherosclerotic disease. The covariation between 
cystatin C and CVD in males indicates that cystatin C and CVD share genetic influences. 
Variation in cystatin C is associated with incident myocardial infarction and stroke 
independent of traditional risk factors, with a stronger association to stroke. The finding that 
cystatin C is related to incident stroke in disease-discordant identical twins indicates that 
individual specific environmental factors are important. One possible explanation is that 
cystatin C may be a sensitive marker of early hypertensive end organ damage. It could be of 
value to expand the usage of cystatin C beyond renal medicine and include it as a tool in the 
arsenal for cardiovascular risk stratification. However, further research is needed. 
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1 INTRODUCTION 
Atherosclerotic cardiovascular disease is the leading cause of death in both men and 
women, with an estimated 17.5 million deaths globally in 2012. Further, according to 
World Health Organization (WHO) estimates, cardiovascular disease as cause of death 
will increase in both high and low income countries over the next 15 years.
1,2
 Within the 
coming decades it is estimated that the loss of disability-adjusted life years (DALYs) are 
expected to rise, from 85 million DALYs in 1990 to 150 million DALYs globally in 2020, 
making it the leading somatic cause of loss of productivity.
3
 The main underlying cause of 
cardiovascular disease, atherosclerosis, and its complications are thus of major importance 
to public health worldwide. 
Risk factors for the development of cardiovascular disease have been thoroughly studied
4
 
and big efforts and progress have been made in identifying subjects at increased risk. 
Traditional risk factors such as age, gender, smoking, hypertension, blood lipids and 
heredity are combined when estimating an individuals’ risk of future cardiovascular 
disease.  However, medical endeavors in recent decades have substantially increased 
survival in patients with cardiovascular disease, creating a growing elderly population 
with a high prevalence of established cardiovascular disease and cardiovascular risk 
factors. Traditional risk factors lose some of their predictive ability with increasing age
5
 
and their predictive ability in established disease is not as well studied in healthy cohorts. 
In order to identify new markers to improve risk assessment in elderly persons and in 
persons with known cardiovascular disease it is of importance to identify new predictive 
markers.  
Cystatin C, first and foremost known as a marker of renal function and considered a better 
marker of glomerular filtration rate (GFR) than serum creatinine, has been suggested as a 
possible independent biomarker of cardiovascular disease (CVD).
6
 Chronic kidney 
disease (CKD) and cardiovascular disease share common risk factors and often coexist 
and therefore the relation between cystatin C and CVD is intricate and causal mechanisms 
are difficult to study. To study the relative importance of how genetic and environmental 
factors influence variations in cystatin C, how they influence the development of 
atherosclerosis, and how they influence the association between cystatin C and CVD, may 
provide new important new knowledge on this relation.  
The overall aim of this thesis has been to study the relation between cystatin C and 
cardiovascular disease, to investigate if it may be used as a biomarker for atherosclerotic 
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disease, and if it could lead to earlier identification of patients at particularly high risk. In 
addition, we investigated the heritability of cystatin C and its relation to heritability of 
cardiovascular disease. Finally we studied the predictive value of cystatin C when 
controlled for genetic confounding in twin studies.  
  3 
2 BACKGROUND 
2.1 CARDIOVASCULAR DISEASE 
Cardiovascular disease (CVD) is a heterogeneous group of disorders related to the heart and 
blood vessels. They can be further divided into CVD  due to atherosclerosis and other 
CVDs.
7
 The first group includes: coronary heart disease (CHD) such as myocardial infarction 
(MI), cerebrovascular disease, e.g. stroke and peripheral artery disease (PAD), for example 
intermittent claudication. It is sometimes narrowed down to “hard” atherosclerotic 
cardiovascular disease (ASCVD), such as in the American College of Cardiology 
(ACC)/American Heart Association (AHA) guidelines, where it is defined as coronary death 
or nonfatal myocardial infarction, or fatal or nonfatal stroke.
8
 The latter group, which will not 
be further discussed in this work, includes: rheumatic heart disease, congenital heart disease, 
cardiomyopathies and arrhythmias.  
The onset of atherosclerotic cardiovascular disease starts as early as during fetal life
9,10
 and 
gradually progresses throughout life. By the time the first symptoms occur disease is often 
quite advanced. Development of atherosclerotic CVD is the result of a vast number of factors 
that, added together, leads to disease manifestation.
11
 These factors are both of a preventable 
kind such as smoking, unhealthy diet habits and physical inactivity, as well as of  non-
preventable kind where age, gender, ethnicity, heritability and medical history are the core 
elements.
12
 In individuals with a family-history of CVD the risk for CVD is higher than in 
individuals without one.
13
 This is mainly attributed to the fact that conventional risk factors, 
due to shared genetics and shared environment,
14,15
 are markedly higher in individuals with a 
family-history of CVD,
16
 but does not explain all of the difference.
17
 One hypothesis for the 
unexplained difference in risk for CVD between individuals with a family history of CVD 
and those without, is that the normal vascular ageing process take on a more rapid course 
defined as early vascular ageing (EVA).
18
 This process may include the morphological 
changes of arteriosclerosis such as vessel wall thickening and arterial stiffness due to loss of 
elasticity, molecular alterations such as declining endothelial function, 
19,20
 and the 
characteristic changes associated with the atherosclerotic process, such as smooth muscle 
proliferation and plaque and lesion formation.   
2.2 ATHEROSCLEROSIS 
Atherosclerosis is a complex chronic inflammatory process engaging the walls of arterial 
blood vessels
21
 developing over many years. The process includes the uptake of low-
density lipoproteins (LDL) in the arterial wall, oxidation of LDL, which generates an 
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inflammatory reaction with leukocyte infiltration into the vessel wall and uptake of LDL 
into macrophages, with the formation of foam cells.
22
 Smooth muscle cells migrate within 
the vessel wall, forming a fibrous coat around the plaque, but this coat can be weakened 
which in turn may lead to plaque rupture and thrombosis. This ultimately lead to 
complications such as acute myocardial infarction (AMI) and stroke, which together 
amounts to roughly eighty percent of all cardiovascular (CV) death in both sexes 
worldwide.
7
  
One of the most prominent clinical manifestations of atherosclerosis is peripheral arterial 
disease. The main morphological feature of PAD is arterial stiffening,
23
 arteriosclerosis, 
which in turn leads to arterial remodeling, vessel wall thickening, atheroma buildup and lastly 
atherosclerotic plaque rupture.
24,25
 Symptoms range from intermittent claudication, with 
painful cramping in the lower extremities during physical activity to ischemic ulcers and 
critical limb ischemia, which ultimately may result in amputation of parts of the 
extremity.
26
 Peripheral artery disease is common, but since it is often asymptomatic the 
prevalence is hard to estimate. A population based study in 5000 individuals reported a 
prevalence of >18% for persons 60-90 years in Sweden.
27
  It is also associated with a high 
frequency of concomitant coronary artery disease (CAD) which is often silent 
28
 and 
patients are also at increased risk for other cardiovascular events.
29,30
 
2.2.1 Remodeling of the extracellular matrix 
One important component in the atherosclerotic process is the remodeling of the 
extracellular matrix in the adjacent vessel wall around the plaque.
31
 This process is related 
to changes in the vessel wall called arteriosclerosis, that occur in normal vascular ageing, as 
a consequence of adaptive mechanisms to preserve normal conditions of blood-flow and 
wall tension.
32
  
Proteolytic enzymes have the ability to degrade components of the extracellular matrix, 
such as elastin and collagen, by elastinolysis and collagenolysis. These can be seen as 
compensatory mechanisms and they are important in the progression of atherosclerosis and 
aneurysm development.
33,34
 Matrix metalloproteinases are examples of such proteolytic 
enzymes that have received considerable attention.
35,36
 More recently it has been shown that 
also cathepsin-family cysteine proteases are important proteins in the elastinolytic process. 
This group includes several proteins, such as Cathepsin S and K, which can be measured in 
serum and therefore have been proposed as possible biomarkers for atherosclerotic 
disease.
37-39
 A natural inhibitor of the cathepsin cysteine proteases is cystatin C.
40
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2.3 CHRONIC KIDNEY DISEASE IN RELATION TO CVD 
Decreased glomerular filtration rate(GFR) is a known risk factor for the development of 
cardiovascular disease in subjects with mildly reduced kidney function as well as in 
individuals with established chronic kidney disease,
41-43
 and merely microalbuminuria is 
associated with increased risk for coronary events independently.
44
 Therefore, early 
identification of chronic kidney disease on the basis of proteinuria alone or together with 
reduced glomerular filtration rate is important in order to permit early intervention.
45
 
Individuals with chronic kidney disease have a higher risk of dying from cardiovascular 
disease than from kidney failure.
46
 Although much of the risk of CKD is due to its association 
with other traditional CVD risk factors, such as more severe hypertension or dyslipidemia, 
several studies have noted that the traditional Framingham risk-factors for CVD do not 
sufficiently capture the CVD risk in CKD patients.
47
 If this is an effect due to non-traditional 
risk factors or an altered effect of traditional risk factors in CKD patients, or if it is the 
presence of CKD in itself that is an independent risk factor for CVD outcomes, is not yet 
fully understood.
48
   
2.3.1 Creatinine 
The gold standard for measuring renal function is by measuring the clearance rate of injected 
substances such as inulin or iohexol.
49
 These are both precise, but invasive, time consuming 
and expensive methods and therefore of limited clinical use.
50
 In the mid 1930’s the clearance 
of endogenous creatinine, a 113D amino acid,
51
 was proposed to reflect the glomerular 
filtration rate.
52
 Ever since, it has been a favored analysis, both in urine and serum, for 
approximating kidney function in general and glomerular filtration rate in particular. 
However glomerular filtration rate is merely one of several factors that determines creatinine 
concentration.
50
  
The generation of serum creatinine is primarily the result of non-enzymatic dehydration of 
muscle creatine
53
 and the diary intake of creatinine from heated meat.
54
 Thus, muscle-wasting 
conditions such as glucocorticoid medication
55
 and diseases such as Duchenne’s muscle 
dystrophy and myasthenia gravis
56
 will also affect serum creatinine, as will sex,
57
 cachexia 
and natural ageing.
58
  
The renal handling of creatinine is a complex matter since creatinine does fulfill some, but 
not all, requirements for a perfect filtration marker. It is freely filtered, not protein bound, not 
metabolized by the kidney and it’s physiologically inert.50 However it is partly secreted by 
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the proximal tubuli, making creatinine clearance (CCr) based GFR uncertain in some cases.
59
 
There are also indications that decreased urinary output, such as in patients with 
decompensated heart failure, may cause tubular reabsorption of creatinine.
60,61
 Some drugs, 
for example trimethoprim, will inhibit creatinine secretion and thus reduce creatinine 
clearance, which will lead to an increased creatinine level without affecting the GFR.
62
 There 
is also an extrarenal creatinine elimination pathway in the gastrointestinal tract mainly seen in 
patients with heavily reduced GFR, whereby creatinine from intestinal secretions is degraded 
by bacteria of the gut.
63
 
2.3.2 Estimation of kidney function from endogenous biomarkers 
The inaccuracy of creatinine as an endogenous marker of GFR has led to the development of 
several formulae to circumvent these shortcomings. These estimations often include, age, sex, 
race and body size in addition to the serum biomarker.
64
 One of the earliest formulas 
developed to estimate GFR from creatinine was the Cockcroft-Gault formula developed in 
the early 1970’s with data from 250 men.65 After some corrections, it was later also validated 
for use in women.
66
  It has been observed that this formula systematically overestimates GFR, 
particularly in individuals with GFR <60 mL/min/1.73m
2
.
67
 
In the late 1990’s the Modification of Diet in Renal Disease Study (MDRD) formulated a 
new creatinine based equation.
68
 This formula has been found to perform equal or better than 
the Cockcroft-Gault formula in most populations
64
 but it has been observed that it is 
imprecise in patients with normal or only mildly reduced kidney function where it 
underestimates GFR.
69
  
The Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI) was 
introduced in 2009 and uses the same variables as MDRD but it has  proven to be more 
correct, especially in subjects with GFR >60ml/min/1.73m
2
.
 70 
Further, the CKD-EPI 
equation is the only formula that is also developed for standardized cystatin C,
71
 and using a 
combination of creatinine and cystatin C in the equation has proved to be the most accurate 
way to estimate GFR across the whole range of GFR as well as in different subgroups.
72
 
Lastly albumin/creatinine-ratio (ACR) is a way to detect microalbuminuria, which may be an 
early sign of renal disease before it is detectable as a decrease in GFR.
73
   
 
  7 
2.4 CYSTATIN C  
 
Cystatin C is a low molecular weight basic protein (13,343-59 Da),
74
 first described in 1961 
as γ-trace or post-γ-globulin when it was isolated in normal cerebrospinal fluid and urine 
from patients with renal failure.
75,76
 Later its presence has also been shown in serum, saliva, 
seminal and synovial fluid.
77
 In the early nineteen eighties, it was recognized as a 120 
amino acid residues polypeptide, functioning as a cysteine protease inhibitor, located on 
chromosome 20 and renamed cystatin C.
78-80
 The cystatin C gene, called CST3, is of the 
housekeeping type, meaning that it is required for the maintenance of basic cellular 
function.
79,81
 It is expressed in all nuclei bearing cells, which produces and secretes cystatin 
C at a fairly constant rate.
80
 Cystatin C belongs to Family 2 of the cystatin superfamily. 
This protein family consists of cystatins C, D, E/M, F, G, S, SA and SB which mainly exert 
extra- and transcellular effects.
82
 The cystatins have several characteristics in common, with 
the ability to inhibit almost all papain-like (family C1) cysteine endopeptidases being the 
most significant, and each cystatin molecule have a single reactive site for each peptidase it 
inhibits.
83
  
2.4.1.1 Cystatin C and relation to kidney function 
Cystatin C has proven to be almost freely filtered in the renal glomeruli and fully 
metabolized after tubular reabsorption.
84,85
  Normal plasma levels for cystatin C in adult 
healthy individuals ranges between approximately 0.5-1.2 mg/L but rises reciprocally with 
the reduction of glomerular filtration rate.
85,86
  Several studies have indicated that cystatin C 
is more precise than creatinine in estimating glomerular filtration rate,
87,88
 especially in 
older populations, 
89
 and that it improves CKD detection (defined as estimated GFR 
<60ml/min/1.73m
2
). Cystatin C may thus be better at predicting end-stage renal disease and 
all-cause mortality.
72,90
  In contrast to creatinine-based formulas such as MDRD and 
Cockcroft-Gault, cystatin C-based GFR estimations do not need to take factors such as age, 
body mass and gender into account.
91-93
 Therefore the use of cystatin C as a marker of renal 
function has increased in clinical practice, although there are a few certain situations where 
cystatin C’s reliability as a marker of kidney function may be limited, such as in patients 
with thyroid disease, malignancy and during corticosteroid use. 
94
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2.4.1.2 Cystatin C and Cardiovascular Disease 
Several epidemiological studies have suggested that cystatin C, besides being a marker of 
GFR, is associated with numerous different clinical outcomes such as heart failure, risk for 
infection and all-cause mortality.
95-97
 Besides this, it has been proposed that cystatin C 
could be used as an independent biomarker for cardiovascular disease.
6,97
 One possible 
rationale for this independent association is that cystatin C is an important natural inhibitor 
of cysteine proteases such as the cathepsins B, H, K, L and S, which has a central role in the 
remodeling elastinolysis of the vessel wall that is an important part of the atherosclerotic 
process.
31,98
 There is also some evidence that cystatin C is associated with early stage 
arteriosclerosis, defined as increased arterial stiffness measured by cardio-ankle vascular 
index (CAVI),
99
 in subjects with estimated glomerular filtration rate (eGFR) >60mL/min.
100
  
Findings from previous population-based studies have shown that cystatin C is superior to 
creatinine for prediction of incident ASCVD.
101-103
 Whether this is due to unique properties 
of cystatin C that are independently associated to vascular remodeling, and maybe even 
causally involved in the development of ASCVD, has been debated.
82
 Thus it is plausible that 
it primarily is a reflection of cystatin C being a more sensitive marker of early GFR-
reduction.
104
  In this regard cystatin C might be a marker of early vascular ageing, and as such 
detect subclinical manifestation of features such as small vessel degeneration, left ventricular 
heart load, arterial calcification, matrix remodeling and intima alterations.
105,106
 
2.5 CARDIOVASCULAR RISK FACTORS 
Numerous factors have been identified that contribute to a risk profile prone to develop 
cardiovascular disease. Those of greatest importance for the development of myocardial 
infarction in both sexes, at all ages, in all regions worldwide are:  smoking, abnormal lipids, 
history of hypertension or diabetes, abdominal obesity and psychosocial factors. Protective 
factors are: daily consumption of fruits and vegetables, moderate alcohol consumption and 
regular physical activity.
4
 In a global perspective hypertension, smoking, physical inactivity, 
unhealthy diets and harmful use of alcohol are the most important modifiable factors.
7
  
Both genetic- and environmental factors in a complex interplay contribute to the development 
of a risk profile. A distinct example is hypercholesterolemia, which is characterized by 
elevated levels of LDL-cholesterol in plasma that may be attributed both to dietary intake as 
well as a genetic predisposition in the form of familial hypercholesterolemia with hetero or 
homozygotic pathogenic variants in one of three genes (LDLR, APOB, PCSK9).
107
 There is 
also evidence that other single nucleotide polymers (SNPs) associated with levels of LDL are 
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also independently associated with a risk of first myocardial infarction, ischemic stroke, or 
death from coronary heart disease.
108,109
   
2.5.1 Risk scoring and guidelines 
The regional scientific societies, such as the European Society of Cardiology (ESC) and the 
American Heart Association (AHA) regularly publish guidelines to provide health care 
professionals with up to date, evidence based knowledge and recommendations regarding the 
management and prevention of cardiovascular disease.
110,111
 In order to aid physicians in 
estimating cardiovascular risk for clinically healthy individuals, these guidelines include 
risk scoring systems such as the QRISK, the JSB3, the Reynolds risk scores for men and 
women and most recently the ACC/AHA hard ASCVD risk calculator.
8,112-115
  
Two of the most frequently used risk scoring systems are the Framingham Risk Score, 
initially presented in 1998,
116
 and the European SCORE-system from 2003.
117
 The 
Framingham Risk Score was revised into its current form, Framingham/ATPIII in 2002,
118
 
and a version with a broadened endpoint including stroke, heart failure, coronary artery 
disease and peripheral artery disease named Framingham General Cardiovascular Risk 
Score was designed in 2008.
119
  
Both Framingham and SCORE provide a 10-year assessment of cardiovascular risk in 
previously healthy individuals, SCORE for first fatal atherosclerotic event and Framingham 
for general cardiovascular disease risk.
117,119
  Both these scoring systems include age, sex, 
total cholesterol, systolic blood pressure, high-density lipoprotein and smoking.  
Framingham also includes blood pressure treatment and diabetes, whereas SCORE on the 
other hand includes high or low risk region of Europe as a risk factor.  
A general disadvantage of all current risk prediction systems, which are mainly based on the 
Framingham study,
120
 is that they may vary in accuracy between different ethnic groups, 
cultures and ages.
121,122
 Further, none of the scoring systems available today are designed for 
subjects already burdened by cardiovascular disease and coronary heart disease equivalents 
such as PAD, cerebrovascular disease, abdominal aorta aneurysms and diabetes mellitus.
123
 
Patients with any of these conditions present are placed in the high-risk group but current 
guidelines do not offer a further risk stratification within these populations.  
The presence of chronic kidney disease or decreased renal function is only to a limited 
extent considered in current guidelines and scoring systems.  Despite the fact that 
individuals with CKD are at high risk for cardiovascular disease,
124
 and that glomerular 
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filtration rate and albuminuria are consistently associated with elevated cardiovascular risk in 
many different populations,
125
 only JSB3 and QRISK incorporate CKD in the equations. In 
the ESC guidelines on cardiovascular disease from 2012 an estimated GFR < 60 mL/min per 
1.73 m
2
 is viewed to confer high or very high risk, whereas urinary ACR of 30–300 mg/g is 
only viewed to confer risk in patients with diabetes and albumin/creatinine ratio above 300 
mg/g is not considered at all.
111
 The ACC/AHA guideline considers the contribution of both 
CKD and albuminuria to be uncertain and thus issues no recommendations for or against.
8
  
None of the scoring systems recognizes the measurement of estimated glomerular filtration 
rate or ACR as risk factors. 
Most cardiovascular events will occur in individuals at moderate risk. Thus, from an overall 
perspective it makes sense to identify subjects at moderate risk who are in need of preventive 
measures on the basis of their global risk score, derived from all CVD risk markers. 
However, it is individuals within high-risk groups that will have the greatest benefit of 
reducing risk factors
126
 due to a higher reduction of their absolute risk.  
Therefore, in recent years increased emphasis is being placed on reducing the absolute risk 
for the individual instead of reducing the relative risk on group level.
127
 This has led to an 
increasing interest in different blood-biomarkers as they might add to the absolute individual 
risk in elderly populations with cardiovascular disease, where the relevance of traditional risk 
factors decreases.
5
 As of yet though, the only blood-biomarker embraced by current 
guidelines is high sensitive C-Reactive Protein (hs-CRP) and its relevance in enhancement of 
risk improvement is disputed.
128
 Consequently, finding new ways to more accurately predict 
cardiovascular risk, including the development of new biomarkers, is of importance. 
2.6 COMPLEX DISORDERS 
Genetically, atherosclerotic disease belongs to the polygenic, or complex, disorders. This 
means that the development of a disease (phenotype) is a function of a complex relationship 
between several environmental factors and multiple genetic variations.
129
 Unlike Mendelian 
disorders, such as Huntington’s disease, cystic fibrosis or phenylketonuria, which are 
caused by alterations in one gene alone, complex disorders does not obey the Mendelian 
single-gene dominant or recessive patterns of inheritance.
130
 Although the genes associated 
with complex disorders are inherited in the same way, they only make up part of the disease 
pathway. This means that a genetic susceptibility for developing a complex disease may not 
be enough, interaction at the molecular level between genetic products and by-products of 
environmental impact is also needed for the disease phenotype to occur.
131
 Further, the 
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genetic prerequisites for complex disorders are almost invariably due to alterations at more 
than one genetic locus, and interaction between many different loci (epistasis) 
132
 may 
contribute to disease development.  This has been confirmed in large scale association 
analyses that have identified over 45 genetic loci in individuals of European and Asian 
descent associated with cardiovascular disease, whereof 1/3 of loci is also related to the 
traditional risk factors plasma lipids or hypertension.
133-135
 
2.7 QUANTITATIVE GENETICS 
Quantitative genetics is a method to study if observed differences among individuals 
regarding complex traits are due to genetic or environmental differences, or both. The most 
commonly used methods in these types of studies are twin and adoption studies. Many 
heredity studies nowadays also incorporate a molecular genetic method called genome-wide 
complex trait analysis (GCTA) in order to strengthen the findings from the classical 
heritability model.
136
     
2.7.1 Heritability and environment  
The proportion of the variation of a phenotype that is due to heritable (genetic) differences 
between individuals within a study population is referred to as heritability. Heritability can be 
measured in two different ways, broad-sense (H
2
) and narrow-sense (h
2
). The broad-sense 
heritability measures the ultimate ability to predict a phenotype from a genotype as it 
measures the full contribution of genes to the phenotype. This can be broken down further 
into contribution from individual (additive) alleles, contributions due to homologous alleles at 
a specific locus (dominance) and combinations of non-homologous loci (epistasis). The 
narrow sense heritability captures the additive contribution of genes to the trait, which is the 
same as the maximum variance that can be explained by a linear combination of the allele 
counts.
137,138
  
2.7.1.1 Structural equation model (SEM) 
To estimate heritability for the chosen phenotypes the structural equation model (SEM) 
fitting-method decomposes phenotypes into the influence of an additive genetic factor (A), a 
common environmental factor (C) or dominance genetic factor (D), and a unique 
environmental factor (E).
136,139
 The broad-sense heritability is then estimated as either the 
proportion of variance explained by A plus D, if the intra-class correlation in monozygotic 
twins is larger than twice of the correlation in dizygotic twins (ADE-model), or if the intra-
class correlation in monozygotic is less than twice the correlation in dizygotic (ACE-model) 
only by A. 
 12 
2.7.1.2 Bivariate heritability  
In certain circumstances it may be of interest to investigate if the covariance of two, or 
more, phenotypes is due to genetic or environmental factors, for example serum level of 
cystatin C and glomerular filtration rate. This can be accomplished by using bi-, or 
multivariate quantitative genetics.
140
 By utilizing cross-covariance between family members 
it is possible to study whether trait A in a family member is associated with trait B in 
another family member. A genetic correlation of 1.0 implies that all additive genetic factors 
that influence trait A also influence trait B. In analogy, a shared environmental correlation 
of 1.0 suggests that environmental influences that make family members similar with 
regards to trait A also influences family members similarity with regards to trait B to the 
same extent. Consequently, a high genetic correlation in bivariate analysis implies that a 
gene that influences one of the investigated traits is also likely to influence the other 
investigated trait. Another important factor regarding bivariate heritability is that genetic 
correlations are independent of univariate heritabilities. Hence trait A and trait B may both 
have low heritabilities but still have high genetic correlations, implying that even though  
the genetic effect on the phenotypes is small the genes involved most certainly influences 
both traits.
136
 
2.7.1.3 Gene-environment interplay 
The interplay between genes and environment is roughly divided into gene-environment 
correlation and gene-environment interaction. The former is subsequently divided into the 
passive-, evocative- or active type where passive means that children receive genotypes that 
are correlated with family environment, evocative implies that individuals are reacted to on 
the basis of their genetic prerequisites and active assumes that individuals create or seek out 
environments that correlates with their genetic makeup.
141
 Gene environment-interaction is 
usually defined as the effect the environment has on a phenotype on the basis of the 
underlying genotype. A consequence of this is that individuals with predisposing genetics 
may be especially vulnerable to the influence of certain environments.
142
 A theoretical 
example is exposure to ultra violet radiation from the sun, which could lead to unfavorable 
mutations in a susceptible person which in turn eventually leads to development of 
malignant melanomas.  
2.7.2 Twin-study methodology 
The strength of the classic twin study model is due to the fact that it compares monozygotic 
twins, who stems from the same egg and thus share all alleles, with dizygotic twins who are 
developed from two eggs and on average shares 50% of their genome.
143
 These genomic 
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prerequisites, paired with a number of assumptions that need to be accepted, make up the 
basis of the twin study design which makes it possible to study the effects of genetic and 
environmental variance on a specific phenotype.  
In 1875 Sir Francis Galton published the results of his twin studies. Although his studies 
merely focused on the impact of environment on twins and thus did not compare 
resemblance between monozygotic (MZ) and dizygotic (DZ) twins, his studies are 
considered the first of its kind. In these publications, he argues that nature, i.e. genetics, is a 
more important factor than the environment in the development and behavior of twins. He 
also argued that twins originate from the same egg, despite having any heavy evidence for 
this claim. 
A breakthrough regarding the logic of twin study methodology were made through studies 
conducted in the early 1920s by psychologist Curtis Merriman and dermatologist Herman 
Werner Siemens.
144
 Siemens counted the number of birthmarks in MZ-twins and compared 
the result with the number in DZ-twins. He then found the correlation of the number of 
moles in MZ to be 0.4 compared with 0.2 in DZ, who only share half of their genome. This 
conducted him to formulate the hypothesis that all heritable properties will exhibit greater 
similarity in monozygotic than in dizygotic twins.
145
  Thus, by combining classical 
correlation methods with the study of twins the modern twin study was born.  
As a result of the fact that they are born at the same time and place, twins share many 
environmental aspects from the intra-uterine environment through parenting style to 
education and socioeconomic factors. In theory this means that any difference in the 
presence of a specific genetic trait between twins in a MZ pair (discordance) is due to 
unique environmental factors that impact the trait in one but not the other. This can be true 
if the following assumptions are made:  
 the assumption of equal environment, assuming that both MZ- and DZ-twins share 
common environment to the same extent.  
 the assumption of random mating, i e no inbreeding or assortative mating.  
 the assumption of minimal gene-environment interaction/correlation, meaning that 
exposure to environmental conditions is dependent on an individual's genotype. 
 the assumption that there is no difference regarding the investigated traits between 
twins and the general population.
146
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In reality it is possible that one or more of these assumptions do not hold true, which will 
have implications for the result of the twin study, for example the equal environment 
assumption has been largely debated. A violation of this assumption would be if MZ twins 
share more trait relevant environment than do DZ, since this would lead to an increased MZ 
correlation relative to DZ correlation, which in turn can result in an overestimation of the 
genetic effect and an underestimation of the shared environmental effect.
146
  In favor of the 
equal environment assumption is the fact that MZ twins that were brought up apart display 
similar correlations compared to MZ twins who were brought up together.
147
 
By calculating the difference in correlation for a particular phenotype between MZ and DZ 
twins, it is possible to calculate the heritability (h2) of this phenotype.
148
 Heritability, or 
heredity, in the example above is therefore ((0.4 - 0.2) x 2) = 40%. Often, it is of interest to 
calculate to what extent a common environment affects the expression of a particular property 
or disease. This can be done by calculating the difference between total correlation within the 
MZ twin group and the heritability (h2). In a Swedish study of antisocial behavior in girls a 
correlation of 0.82 in MZ and 0.45 in DZ was calculated, which gives an h2 of 74%.
149
 On 
the basis of this it’s possible to consequently estimate a common environmental factor of 8% 
(0.82 - 0.74). The difference between perfect correlation of 100% and the measured 
correlation in MZ, in this case 1.0 - 0.82 = 0.18, is said to arise from individual specific 
environmental factors. 
2.7.3 Genome-wide Complex Trait Analysis (GCTA) 
Genome-wide complex trait analysis is a recently developed method whereby the proportion 
of variance of a complex trait that is explained by common genetic variation is estimated 
using single nucleotide polymorphism- markers(SNPs).
150
 Contrary to the twin design, 
GCTA does not rely on familial resemblance. Instead it uses thousands of individuals to find 
genetic similarity across hundreds of thousands of SNPs. The power of the method lies in the 
fact that it can extract tiny signals of genetic similarity from the hundreds of thousands of 
SNPs investigated by comparing them for each pair of individuals in a matrix of thousands of 
unrelated individuals.
136
 One of the major advantages of the method is that the heritability 
estimated comes directly from measured DNA differences between the unrelated individuals, 
thus making it a between-family analysis method as opposed to a twin structured equation 
model (SEM) that is within family. Thus, the twin-SEM and GCTA is not directly 
comparable since GCTA is restricted to additive contribution from common variants while 
twin-SEM can capture both additive and dominance from both common and rare variants. 
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GCTA can also be extended to bivariate heritability analysis,
151
 and in contrast with 
univariate analysis bivariate estimates of genetic correlation from GCTA are similar to 
estimates from twin studies, as GCTA estimates of genetic correlations are unbiased.
152
  
2.8 BACKGROUND SUMMARY 
Various manifestations of atherosclerotic cardiovascular disease are a common clinical 
problem affecting millions of people each year.
1,3
 The fact that both prevalence and incidence 
increases globally
2
 strengthens the incentives to improve the tools for both primary and 
secondary prevention.  Identifying new potential ways to use established biomarkers may 
allow for earlier and more precise identification of high risk individuals and take preventive 
measures before patients suffer complications. Increased knowledge of the above relations 
may also eventually provide new therapeutic opportunities. 
Cystatin C is a promising biomarker of vascular damage and vascular disease,
6,97
 that might 
add value to risk prediction in cardiovascular burdened individuals as well as in persons free 
of cardiovascular disease. Patients with peripheral arterial disease are an interesting group to 
study with regards to cystatin C since manifest disease features both arteriosclerosis and 
atherosclerosis and thus is well suited for studies of possible connections between these 
conditions and cystatin C.  Further they are a, often undertreated, group with high 
cardiovascular risk where coronary artery disease is the major cause of death
6,29,153
 and they 
are in need of improved tools for risk prediction.  
Cystatin C serves as an endogenous marker of glomerular filtration rate, possibly less biased 
than creatinine.
92
 Chronic kidney disease is a known risk factor of CVD.
44
 Nevertheless, 
chronic kidney disease and cardiovascular disease share common risk factors and often 
coexist. Therefore the relation between cystatin C and CVD is intricate and causal 
mechanisms are difficult to study.  
Atherosclerotic cardiovascular diseases are polygenic disorders and disease development is a 
function of complex relationships between several environmental factors and multiple 
genetic variations.
129
 To study the relative importance of how genetic and environmental 
factors influence variations in cystatin C, how they influence the development of 
atherosclerosis, and how they influence the association between cystatin C and CVD, may 
provide new important new knowledge on their relation. The main purpose of this thesis was 
to further investigate these gaps in knowledge.   
 
  17 
3 AIMS OF THE THESIS 
The overall aim of this thesis is to deepen the understanding about the relation between 
cystatin C and cardiovascular disease. We wanted to investigate whether cystatin C could be 
used as a biochemical marker for atherosclerotic cardiovascular disease (Study I) and if it had 
prognostic value in cardiovascular patients (Study II). In addition, we intended to estimate the 
heritability of cystatin C (Study III) and to investigate which role genetics and environment 
have on the relationship between cystatin C and prevalent (Study III) as well as incident 
(Study IV) cardiovascular disease. 
Specific objectives of the respective sub–studies: 
3.1 STUDY I 
- To investigate if cystatin C, independent of its function as a marker of glomerular filtration, 
could be an independent marker of peripheral arterial disease. 
3.2 STUDY II 
-To examine the predictive value of cystatin C in patients with PAD. Secondary aims were to 
study whether predictive models including cystatin C resulted in better discrimination and 
correctly reclassified patients in comparison with a model containing other significant risk 
factors previously identified in this cohort. 
3.3 STUDY III 
- To estimate the relative importance of genes for the phenotypic variability of cystatin C and 
creatinine levels, in a well-powered twin study. A secondary aim was to study the relation of 
heritability of cystatin C and creatinine to the heritability of cardiovascular disease. 
3.4 STUDY IV 
- To study if variations in levels of cystatin C, predicts incident atherosclerotic cardiovascular 
disease when controlled for traditional risk factors and genetic factors. A secondary aim was 
to study the association of cystatin C to incident MI and stroke respectively. 
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4 SUBJECTS AND METHODS 
4.1 SUBJECTS 
4.1.1 Study I & II 
Study participants were consecutively recruited from patients referred for symptoms of 
intermittent claudication to the vascular clinics of Karolinska and S:t Göran hospitals, 
Stockholm, Sweden, between 1998 and 2001. Inclusion criteria were male sex, age >45, a 
history of intermittent claudication (leg pain at exercise with prompt relief at rest and not 
explained by another condition), and an ankle-to-brachial systolic pressure index (ABI) <0.9 
by Doppler ultrasonography at rest based on initial study examination. Twenty-seven patients 
had a history of previous peripheral vascular surgery. In these patients, a higher baseline ABI 
than <0.9 at the time of the study investigation was accepted. Patients with rest pain, previous 
amputation, or reasons for a reduced walking performance other than intermittent 
claudication, diabetes mellitus type 1, and atrial fibrillation were excluded. A history of 
ischemic heart disease was not an exclusion criterion, and patients were included irrespective 
of presence of ischemic heart disease. To confirm the intermittent claudication diagnosis all 
patients and control subjects performed a standardized exercise treadmill test. Referred 
patients that met the inclusion criteria were asked for informed consent to participate in the 
study.  
A total of 103 respectively 99 patients with intermittent claudication met the inclusion criteria 
for participation in study I and II. In one patient, ambulatory blood pressure (ABP) 
monitoring was not performed since office systolic blood pressure (SBP) was repeatedly 
>210 mm Hg, leaving 98 patients for the final analysis in study II. No alteration of 
medication was done before the investigations. 
 Potential control subjects matched for sex and age were consecutively drawn from the 
population registry of Stockholm County. Eligible subjects were invited to the clinic for a 
screening visit, at which time a medical history, blood pressure, ABI, and a 12-lead 
electrocardiogram were obtained. Subjects who did not have a history of ischemic heart 
disease, stroke, or PAD and with an ABI >0.9 were selected as control subjects. The same 
exclusion criteria applied for patients and controls with regard to type-1 diabetes and atrial 
fibrillation. A total of 96 control subjects were sampled in study I. In study II 92 control 
subjects were sampled, 90 of who performed ambulatory blood pressure monitoring. All 
control subjects provided informed consent. 
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4.1.2 Study III & IV 
Study participants were all obtained from the TwinGene project. TwinGene is a Swedish 
population based cohort of twins born between 1911 and 1958, contacted and enrolled for 
testing between the years 2004-2008.
154
 All eligible participants had previously participated 
in a computer assisted telephone interview called SALT (Screening Across The Life Span 
Twin Study).
155
 Further, both twins within the pairs had to be alive and provide their 
informed consent for study participation. The zygosity of the twins was based on self-
reported childhood resemblance, or by DNA-markers (54% of the study sample). According 
to a recent independent test of the validity of similarity-based zygosity assignments among 
the adults in the TwinGene study there is a dizygotic to monozygotic error rate of 2.56%, 
corresponding to an accuracy of 97.4% (95% CI: 96.6–98.2%) .154 Participants who had 
previously donated DNA for studies in the Swedish Twin Registry (STR) and participants 
who had declined participation in further studies or had a record of hepatitis were excluded. 
In total 12645 individuals donated blood to the project and for these studies serum aliquots 
from a total of 12570 subjects were withdrawn. Of these 257 were excluded due to bad or 
missing sample, non-sufficient sample volume, hemolysis, lipemia or missing donor ID 
leaving a total of 12313 individuals for analysis in study III. Further an additional 911 
subjects with prevalent cardiovascular disease on enrollment were excluded in study IV, 
leaving a total of 11402 individuals for the final analysis. 
4.2 METHODS 
4.2.1 General assessments 
4.2.1.1 Study I & II 
Height was measured, without shoes, to the nearest centimeter, weight, without shoes and 
overcoat, to the nearest kilogram and body mass index (BMI) was calculated (kg/m2). Waist 
and hip circumference was measured in cm and waist/hip ratio calculated. Waist 
circumference was measured directly on the body surface midway between the lower rib 
margin and iliac crest. Hip circumference was measured over light clothing at the widest girth 
of the hip. Ambulatory blood pressure values were obtained using a non-invasive 
oscillometric system (Spacelabs 90207, Spacelabs Inc., Redmond, WA, USA). Blood 
pressure and heart rate were recorded automatically every 15 min for a 24-h period. Office 
BP was recorded in both arms by an experienced nurse using a mercury sphygmomanometer 
with the subject in the supine position after 5 minutes of rest. The mean of two consecutive 
readings was calculated. If there was a difference in systolic or diastolic blood pressure 
between the arms of >10 mm Hg, the arm with the highest reading was used when defining 
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office blood pressure; otherwise the non-dominant arm was used.
156
 The same arm was used 
for office and ambulatory blood pressure measurements. 
4.2.1.2 Study III & IV 
Study participants were asked to make an appointment at their local healthcare facility 
Monday to Thursday for a morning visit. The subjects’ height, weight, hip, and waist 
circumference was recorded without shoes and in light clothing. Participants were asked to 
rest for 5 minutes, thereafter systolic and diastolic blood pressure was measured with the 
subject in upright sitting position. A second blood pressure was taken after 1 minute.  
Through the SALT computer assisted telephone interviews 
155
 data regarding birth order and 
weight, similarity with sibling, contact with twin partner, common illnesses, prescription and 
nonprescription medication use, consumption of alcohol, tobacco and caffeine was collected 
by trained interviewers with adequate medical background. 
4.2.2 Laboratory examinations 
4.2.2.1 Study I & II 
Fasting venous blood samples were drawn and analyzed for creatinine 
157
(Study I & II) and 
HbA1c (Study I). Creatinine clearance was calculated according to Cockcroft’s formula65 
(Study I). GFR was calculated according to MDRD from creatinine age, race and gender 
(Study I & II).
68,158
 The distribution of the estimated GFR was divided into four categories 
(less than 45.0, 45.0–59.9, 60.0–74.9, and at least 75.0 mL/min/1.73m2) according to the 
guidelines of the National Kidney Foundation (Study I).
73
Additional blood samples were 
collected for the determination of serum IL-6 (Study I), cystatin C and high sensitive CRP 
(hsCRP) (Study I & II). Cystatin C and hsCRP were quantitated according to the instructions 
of the manufacturer using particle-enhanced immunonephelometric assays with kits and 
instrument (BN II analyzer) from Dade Behring GmBH, Marburg, Germany. 
159
 The total 
coefficient of variation for cystatin C at 1.2 mg/L was < 3.5%. Total coefficient of variation 
for hsCRP = 3.9% at concentrations below 10 mg/L. IL-6 was measured using a high 
sensitive ELSA kit according to the instructions of the manufacturer (HS600, R&D Systems, 
Minneapolis, MN, USA). The lower detection limit was 0.1 pg/mL (Study I & II). The total 
coefficient variation for IL-6 was <7%. HbA1c was determined using a chromatographic 
(FPLC, Pharmacia BTG) method  with a reference interval <5.2% and a total CV< 3% (Study 
I ). Fasting venous blood samples for NT-proBNP determination were collected in 
ethylenediamine-tetraacetic acid-containing tubes. The samples were then centrifuged, and 
plasma was stored frozen in aliquots at −70 °C within 30 minutes. Plasma NT-proBNP 
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concentration was measured using a commercial test kit and instrument (ELECSYS 2010; 
Roche Diagnostics, Basel, Switzerland), with a reported coefficient of variation of 3.3% 
(Study II).
160
  
4.2.2.2 Study III & IV 
Participants were instructed to fast from 8 PM on the night before the blood sampling. A 
sample volume of totally 50 mL of venous blood was drawn from each participant. Tubes 
with serum and whole blood for clinical chemistry analyses and DNA extraction were sent by 
overnight mail to KI Biobank. Serum samples were aliquoted by Tecan-robot into 1 mL 
fractions and placed in 1.8 mL cryotubes that were stored in liquid nitrogen tanks at the KI 
Biobank. Serum aliquots from participating subjects were then withdrawn, thawed and 
directly shipped off to laboratory for clinical blood analysis.  Clinical blood assessments were 
performed at the Department of Clinical Chemistry and Pharmacology, University Hospital, 
Uppsala, Sweden. Serum samples were analyzed on Abbott Architect ci8200 and ci16200 
instruments (Abbott Park, IL, USA). Reagents for the enzymatic creatinine method were 
from Abbott. Reagents for the immunoturbidimetric cystatin C method were from Gentian 
(Moss, Norway). Calculations of estimated glomerular filtration rate were performed with the 
CKD-epi formula according to Inker et al.
72
  
4.2.3 Twin contact and age at separation 
In study  III & IV data on self-reported intra pair contact frequency, meaning the frequency 
by which the twins in a pair met each other, and age at separation was obtained from the 
SALT interviews. Data on contact frequency by at least one of the twins in a pair was 
available for 11 920 (97%) of the study participants. Contact frequency data was coded into 4 
levels; (1) twins met each other less than once a year; (2) twins met on a yearly basis; (3) 
twins met on a monthly basis; (4) twins met on a weekly basis. Where both twins had 
reported age at separation, average value was used for analysis. By computing the rank-order 
correlation (Spearman) between contact frequency and the absolute intra-pair difference in 
adjusted trait-levels, we explored if contact frequency and the degree of shared-environment 
influences, such as age at separation from co-twin, was associated with similarity in trait 
levels. 
4.2.4 DNA extraction and genotyping 
DNA extraction for use in GCTA in study III was made using Puregene extraction kit (Gentra 
systems, Minneapolis, MN) on a 7 mL EDTA tube of blood. Subsequently DNA was stored 
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at _20°C. Subjects in whom the DNA concentration in the stock-solution was below 20 ng/L, 
as well as subset of 302 female monozygous twin pairs participating in a previous genome-
wide effort was excluded. Thereafter, DNA from all available DZ twins+1 twin from each 
available MZ twin pair (n=9896) was sent to Uppsala, Sweden for genome-wide genotyping 
using the Illumina OmniExpress bead chip. Genotyping results for 9836 subjects and 731 442 
autosomal SNPs passed the initial laboratory based quality control (QC). In further QC SNPs 
with missing information exceeding 3% (GENO>0.03) (n=3922), a minor allele frequency of 
less than 1% (n=79 893) or a Hardy-Weinberg equilibrium (HWE) test P value ≤1E-07 
(n=3071), were excluded. Individuals with low genotyping success (MIND>0.03) (n=10), 
male heterozygosity of X-chromosomes (n=36), deviations in heterozygosity of more than 5 
standard deviations from the population mean (n=49) and/or where unknown (cryptic) 
relatedness (n=124) was detected, were excluded. After the QC there were 9617 individuals 
and 644 556 autosomal SNPs remaining. 
4.2.5 Estimating heritability 
To estimate heritability for the chosen phenotypes in study III two different methods were 
used. First, a classic quantitative biometrical genetic model fitting method where the 
observed variation of each phenotype was decomposed into the influence of additive genetic 
factor (A), common environmental factor (C) or dominance genetic factor (D), and unique 
environmental factor (E).
136,139
 The heritability was estimated as proportion of variance 
explained by A and D in an ADE model (if the intra-class correlation in MZ twins [rMZ] is 
larger than twice of the correlation in DZ twins [rDZ]), or only A in an ACE-model (if rMZ ≤ 
2 * rDZ).  
The second method used to estimate heritability was through genome-wide complex trait 
analysis (GCTA). Variance explained by all SNPs was estimated by restricted maximum 
likelihood (REML) modeling of the genetic relationship matrix (GRM) with phenotype-
levels as implemented in the GCTA version 1.11 software package. 
150
 Since GCTA relies on 
comparisons between subjects that are not closely related, the sample was filtered for close 
relations. For complete monozygotic twin pairs, one twin was randomly selected to be 
genotyped. For complete dizygotic twin-pairs one member of each pair was randomly 
selected rendering the sample reduced to 6634 participants. A further restriction was 
implemented by only considering pair-wise combinations of unrelated subjects with 
relatedness less than 0.025, corresponding to relatedness between second and third cousins, 
which led to exclusion of 999, leaving n=5635 in the final sample on which GCTA-analysis 
was conducted. As there is a risk for bias arising from population stratification, i.e., variance 
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due to systematic ancestry differences due to migration, for example, 
161
 adjustment for 
genetic principal components (PCs) was performed.
162
  Principal components of the genotype 
data significantly correlated to the phenotypes (cystatin C, creatinine and eGFR) were 
identified through a multiple stepwise regression analysis. As data on PCs for all individuals 
were not available (not all phenotyped subjects had been genotyped), a sub-analysis of all 
phenotypes adjusted for significant PCs were then made in order to investigate the magnitude 
of the influence from them. 
4.2.6 Survival and hospitalization data 
4.2.6.1 The Swedish National Patient Register 
The Swedish National Board on Health and Welfare has provided data on in-patient care and 
hospital discharge diagnosis according to the International Classification of Disorders (ICD) 
codes in the National Patient Register since 1964.  The National Patient Register includes 
hospitalized cases, as well as outpatient visits, but not visits to the primary care. External 
validation of the registry show high reliability with positive predictive values between 85-
95% with low drop-out rates. The positive predictive value (i.e., validity) of the myocardial 
infarction diagnosis has been demonstrated to be 95% when only primary diagnoses are 
considered.
163
 The validity of the stroke diagnosis in the registry has been reported to be 
92%.
164
 
4.2.6.2 The Cause of Death Register 
All deceased Swedish citizens are registered in the Cause of Death Register. Data contains 
date, location, ICD-code and main contributory causes of death. The register is also 
maintained by the Swedish National Board on Health and Welfare. External validation has 
shown correct diagnosis in 77% in general, 87% for ischemic heart disease and 68% for 
cerebrovascular disease.
165
 
4.2.7 Statistics 
4.2.7.1 Study I 
Levels of cystatin C, Creatinine clearance and GFR were compared between the study 
patients and the control group using t-test and correlation analysis. As the distribution of IL-6 
and CRP levels were markedly skewed, non-parametric statistics were used to analyze these 
variables (Mann–WhitneyU-test). A backward stepwise multiple regression analysis was 
performed with cystatin C as dependent variable in the total population. The independent 
variables entered in the analysis were PAD, GFR, body mass index, age, waist circumference 
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HbA1c, 24 h pulse pressure (PP) and log IL-6. In order to analyze the separate effect of PAD 
on serum cystatin C-levels and the possible interaction between PAD and renal impairment 
an analysis of covariance (ANCOVA) was used. PAD and GFR-classification was entered as 
categorical independent variables and age, log IL-6 was entered as covariates in this analysis. 
Statistical analysis and database management were performed with Stat Soft, Inc. (2001). 
STATISTICA (data analysis software system), version 7. The authors had full access to the 
data and take responsibility for its integrity.  
4.2.7.2 Study II 
The PAD patients were divided into those with and without events and compared regarding 
biomarkers, ambulatory pulse pressure, and other variables. Further, the incidence of events 
was compared between high vs low tertiles of biomarkers and ambulatory pulse pressure. 
Because the distribution of the biomarkers NT-proBNP, hs-CRP, and cystatin C were 
skewed, logarithmic values were used in the final analyses. In addition, because a U-shaped 
relation between cystatin C levels and cardio vascular events was seen, a quadratic and 
centered term for cystatin C was analyzed. The  predictive value of 24-hour pulse pressure , 
age, biomarkers, and relevant clinical variables were assessed by univariate Cox regression 
analysis, and hazard ratios  for a 1 SD increase (with 95% CI) were calculated for 24-hour 
pulse pressure and logarithmic values of biomarkers. Ambulatory blood pressure variables, 
office blood pressure variables, log(hs-CRP), log(NT-proBNP), and log(cystatin C) were 
separately adjusted for basic cardiovascular risk factors (age, treatment with blood pressure-
lowering drugs, and previous MI) in multivariable analysis. Further the biomarkers were 
separately adjusted for basic cardiovascular risk factors and 24-hour pulse pressure, day pulse 
pressure, night pulse pressure, and night systolic blood pressure, respectively, because these 
ambulatory blood pressure variables were significant predictors in a univariate analysis 
reported previously.
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 Finally, backward variable selection from all of the above (P to enter 
<0.05; P to remove >0.10) was performed to determine independent predictors in a 
multivariable Cox regression analysis. No interactions were found among included variables 
in interactional analysis. Statistical analysis and database management were performed with 
StatSoft (2010) STATISTICA data analysis software system version 9.1 (www.statsoft.com). 
Student t-tests, Mann–Whitney U tests, or χ2 tests were used for dependent or independent 
variables when appropriate. For linear correlation person r correlation coefficient was used. 
4.2.7.3 Study III 
Initial data handling and descriptive statistics were performed in SAS version 9.3 (SAS 
Institute, Cary, NC). To examine differences in variability and means between monozygotic 
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and dizygotic twins a t-test was performed. The distributions of cystatin C, creatinine and 
MDRD were skewed and these variables were log transformed in order to achieve 
approximate normal distributions. Before further investigations, traits for logarithmized 
cystatin C and creatinine together with machine estimated-GFR were adjusted for age and 
sex by linear regression models. In order to estimate GFR according to MDRD and the 
different CKD-epi formulas, age and sex were included in the calculations and thus no 
further adjustment was made for those covariates. After these adjustments, the residuals 
were z-score transformed and the influence of outliers was restrained through winsorizing 
outliers to -4 and +4 SDs. 
 
In order to estimate variance components for each phenotype, maximum likelihood 
estimation and model fitting were performed using the structural equation statistical 
package OpenMx in R (http://openmx.psyc.virginia.edu). In univariate twin analyses the 
adjusted values of the investigated phenotypes were fitted into an ACE or ADE model.
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We conducted a bivariate heritability analysis to estimate the relative importance of genetic, 
common, and unique environmental influence to the phenotypic correlation between 
cystatin C and creatinine. We also tested whether the genetic influence on cystatin C and 
creatinine were correlated to the genetic influence on cardiovascular morbidity in terms of 
manifest CVD. Based on the univariate models, an ACE model was preferred for CVD, 
whereas an ADE was preferred for cystatin C and creatinine. Because we cannot estimate 
the effect of A, D, C, E simultaneously with data from MZ and DZ twins only, ACE 
models were fitted for all bivariate twin analyses to keep consistency. Liability threshold 
model was applied to the dichotomous variable (CVD) by assuming that the ordered 
categories reflect an imprecise measurement of an underlying normal distribution of 
liability.
146
 The variance of CVD was constrained to one for calculating its correlation with 
cystatin C/creatinine. Parameter estimates from a bivariate ADE model between cystatin C 
and creatinine can be accessed upon request. The genetic correlation (rA) was calculated as: 
corA/(√(A%trait1))*rA*(√(A%trait2)) where corA was standardized additive genetic covariance, 
A%trait1 and A%trait2 were the proportions of additive genetic variance for the respective 
traits. The common (rC) and unique (rE) environment component correlation was calculated 
similarly: corC/(√ (C%trait1))*rC*(√ (C%trait2)) and corE /(√ (E%trait1))*rE*(√ (E%trait2)). Through 
this the phenotypic correlation could be estimated to corA+corC+corE. Finally the bivariate 
heritability (h
2
biv) was calculated as: corA/(corA+corC+corE), which is the proportion of 
phenotypic correlation explained by genetic correlation. 
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4.2.7.4 Study IV 
The predictive value per SD increase of logarithmized cystatin C for incident stroke, incident 
MI and incident ASCVD, was studied in a Cox-regression survival-analysis adjusted for sex, 
age, systolic blood pressure, diabetes, current smoking, eGFR (creatinine based CKD-epi), 
total cholesterol, HDL and anti-hypertensive medication. A robust sandwich covariance 
matrix estimate was incorporated into the model to account for any intra cluster dependence, 
which otherwise may inflate precision estimates due to correlated (twin-ships) data. 
Same sexed twin pairs discordant for ASCVD and MI during follow up were identified.  
Independent two sample and paired t-tests were performed in order to verify significant 
differences regarding cystatin C levels on group- and pair level between twins with incident 
ASCVD and twins without incident ASCVD. Thereafter a conditional stepwise logistic 
regression analysis was performed in order to verify significant differences regarding cystatin 
C when adjusted for the same covariates as above. Sub-analyses were performed on twins 
discordant for coronary heart disease and stroke.  
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5 RESULTS 
5.1 STUDY I 
Baseline characteristics for the study populations are shown in table 1. Concentration of 
cystatin C was higher in PAD-patients compared to controls; 1.09±0.40 vs. 0.95±0.17 mg/L 
(p < 0.001). There was no significant difference in CCr or GFR between PAD-patients and 
control subjects. Both IL-6 and CRP concentration was higher in the PAD group. 
Table 1 
Main characteristics and laboratory investigations of the study population 
 PAD-patients (n = 103) Control subjects (n = 96) p-value 
Age (years) 68±8 (45–79) 68±8 (45–79)  
BMI (body mass index) 26.6±3.2 (20–35) 25.7±3.7 (18–35) ns 
Waist–hip ratio 0.96±0.05 (0.74–1.13) 0.94±0.05 (0.74–1.05) p < 0.01 
ABI (ankle brachial index) 0.66±0.19 (0.25–1.29) 1.11±0.11 (0.87–1.41) * 
History of hypertension 61 17 p < 0.001 
Diabetes mellitus type II (yes) 16 7 ns 
Clinical ischemic heart disease 44 0 * 
Calculated creatinine clearance (mL/min) 81±27 82±22 p = 0.78 
GFR (mL/min/1.73m2) 76±21 79±14 p = 0.30 
Cystatin C (mg/L) 1.09±0.40 0.95±0.17 p < 0.001 
CRP (mg/L) 2.63 (1.32, 4.87) 1.45 (0.72, 2.51) p < 0.001 
IL-6 (pg/mL) 1.60 (0.74, 2.85) 0.98 (0.37, 1.70) p < 0.01 
NT-proBNP (pg/mL) 167 (76, 418) 68 (38, 142) p < 0.001 
HbA1c (%) 4.8 (4.6, 5.2) 4.7 (4.5, 4.9) p < 0.001 
S-Cholesterol (mmol/L) 5.4±0.9 5.5±0.9 ns 
HDL (mmol/L) 1.2±0.3 1.3±0.3 p < 0.01 
LDL (mmol/L) 3.4±0.8 3.5±0.8 ns 
S-Triglycerides (mmol/L) 1.7 (1.2, 2.2) 1.3 (0.9, 1.7) p < 0.01 
24-h SBP (mm Hg) 142±14 133±14 p < 0.001 
24-h DBP (mm Hg) 78±8 79±8 ns 
Values are expressed as mean±SD (range), median (interquartiles) or numbers.  
* No statistics performed due to selection criteria. 
When GFR was categorized into normal, mild, moderate and severe renal impairment, more 
PAD-patients had severe and moderate renal impairment as compared to control subjects (p 
< 0.01) (Table 2). 
Table 2 
Number of patients and controls categorized into normal, mild, moderate 
and severe renal impairment based on GFR 
GFR (mL/min/1.73m2) PAD (n = 103) Controls (n = 96) p-values 
≥75 (normal) 61 55 < 0.01 
60–74.9 (mild) 16 33 < 0.01 
45–59.9 (moderate) 16 7 < 0.01 
<45 (severe) 7 0 < 0.01 
 
Table 3 shows the correlations for serum cystatin C-concentration with some clinical and 
laboratory variables in PAD-patients and control subjects. Cystatin C correlated to CCr in 
PAD-patients (r =−0.60, p < 0.001) as well as controls (r =−0.44, p < 0.001). There were 
positive correlations between cystatin C and log IL-6 in both groups (PAD r = 0.35, p < 
0.001 and controls r = 0.38, p < 0.001). A positive correlation was also present between 
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cystatin C and log CRP in both groups (PAD, r = 0.30, p < 0.01 vs. r = 0.32, p < 0.01 
among controls). 
 
Table 3 
Univariate correlation’s between clinical variables and Cystatin concentration in PAD-
patients and control subjects 
 PAD-patients (n = 103) Control subjects (n = 96) 
Age 0.31 (p < 0.01) 0.34 (p < 0.01) 
Body mass index 0.24 (p < 0.05) 0.04 (ns)  
Waist circumference 0.24 (p < 0.05) 0.07 (ns) 
24-h pulse pressure 0.24 (p < 0.05) 0.04 (ns) 
Creatinine clearance (mL/min) −0.61 (p < 0.001) −0.44 (p < 0.001) 
GFR (mL/min/1.73m2) −0.78 (p < 0.001) −0.58 (p < 0.001) 
HbA1c 0.20 (p < 0.05) −0.12 (ns) 
HDL −0.33 (p < 0.01) −0.13 (ns) 
log IL-6 0.35 (p < 0.001) 0.38 (p < 0.001) 
log CRP 0.30 (p < 0.01) 0.32 (p < 0.01) 
logNT pro BNP 0.57 (p < 0.001) 0.42 (p < 0.001) 
Values are Pearson correlation coefficients (p-values) 
In multivariate analysis using the combined population, PAD was a significant predictor of 
the cystatin C-concentration, as well as GFR.  The results of this analysis are shown in 
Table 4.  
Table 4 
Backward stepwise multiple regression analysis of Cystatin C as dependent variable in the combined 
population (n = 199) 
Dependent variable Independent 
variables 
Standard regression 
coefficient 
Standard error of 
regression coefficient 
Significance 
Cystatin C PAD 0.13 0.05 p < 0.01 
R = 0.76, p < 0.0001 Waist circumference 0.10 0.05 p < 0.05 
F(4.182) = 62.9 GFR −0.67 0.05 p < 0.001 
 log IL-6 0.14 0.05 p < 0.001 
Values are expressed as number. 
 
In an analysis of covariance where either GFR or calculated creatinine clearance, as well as 
log IL-6 were added as covariates, cystatin C-concentration remained higher in the PAD-
group(Fig. 1). Further, analysis of covariance showed a significant interaction between 
PAD and GFR-classification on cystatin C-concentration (Fig. 2). 
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Figure 1. Cystatin C-concentration in PAD-patients (n = 103) and control subjects (n = 96). Analysis of covariance with covariates eGFR 
and log IL6. Current effect: F(1.191) = 9.50, p = < 0.01 (computed for covariates at their means). Vertical bars denote 0.95 confidence 
intervals (CI). 
 
 
 
 
 
Figure 2. Interaction between PAD and eGFR-classification on Cystatin C-concentration. Analysis of covariance with covariates age, 
waist circumference and log IL6. Least Squares Means (computed for covariates at their means). Vertical bars denote 0.95 confidence 
intervals (CI).  
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5.2 STUDY II 
Baseline patient characteristics are summarized in Table 5. The median observation time 
was 71 (range = 50–88) months. A total of 55 events occurred in 36 of 98 patients, 
including 14 AMI, 7 percutaneous coronary interventions (PCI), 9 coronary by-pass graft 
surgery (CABG), 10 strokes, and 15 cardiovascular (CV) deaths. A total of 8 events 
occurred in 7 of 90 control subjects (1 AMI, 2 PCI, 1 CABG, 3 strokes, and 1 CV death). 
 
 
Table 5  
Main characteristics and laboratory investigations of the study population (n = 188) 
Characteristic PAD patients 
without events  
(n = 62) 
PAD patients 
with events  
(n = 36) 
p-value Control 
subjects 
(n = 90) 
Age, y 67 ± 8 70 ± 6 0.02 68 ± 8 
Smokers, current/former/never 14/45/3 (23/72/5) 9/24/3 (25/67/8) 0.73 15/40/35 
ABI, ankle brachial index 0.67 ± 0.20 0.64 ± 0.18 0.41 1.11 ± 0.11 
Duration of symptomatic IC 2 (1–7) 3.5 (1–10) 0.10 — 
History of hypertension 33 (53) 26 (72) 0.06 14 (16) 
Treatment w BP lowering drugs 38 (61) 32 (89) 0.004 19 (21) 
     ARB 6 (10) 1 (3) 0.20 2 (2) 
     ACE inhibitors 13 (21) 12 (33) 0.18 6 (7) 
     Beta-blockers 19 (31) 15 (42) 0.27 8 (9) 
     Calcium channel blockers 19 (31) 15 (42) 0.27 4 (4) 
     Diuretics 12 (19) 12 (33) 0.12 6 (7) 
Diabetes mellitus type 2 8 (13) 8 (22) 0.23 7 (8) 
Clinical ischemic heart disease 21 (34) 19 (53) 0.07 0 
Previous AMI 10 (16) 13 (36) 0.03 0 
Previous stroke 7 (11) 10 (28) 0.04 0 
Estimated GFR, ml/min/1.73 m
2
 77.4 ± 20.7 73.6 ± 22.7 0.41 80.2 ± 13.8 
Cystatin C, mg/L 0.96 (0.96–1.06) 1.01 (0.86–1.33) 0.37 0.92 (0.82–1.01) 
hs-CRP, mg/L 2.09 (1.04–4,00) 4.08 (1.87–7.11) 0.004 1.46 (0.74–2.56) 
NT-proBNP, ng/L 119 (67–299) 409 (121–1,069) <0.001 59 (36–123) 
24-h SBP, mm Hg 140 ± 13 145 ± 17 0.13 133 ± 14 
24-h DBP, mm Hg 79 ± 8 76 ± 8 0.08 79 ± 8 
24-h pulse pressure, mm Hg 61 ± 10 68 ± 14 0.003 54 ± 10 
Values are expressed as mean ± SD, median (interquartiles), or numbers (percentage). P values denote comparisons between peripheral 
artery disease (PAD) patients with events compared with PAD patients without events using Student t test, Mann–Whitney U test, or χ2 
test where appropriate. Comparisons between PAD patients and control subjects have been reported previously. Abbreviations: 24-h, 24 
hour; ACE, angiotensin-converting enzyme; AMI, acute myocardial infarction; ARB, angiotensin 2 receptor blocker; BP, blood pressure; 
DBP, diastolic blood pressure; GFR, glomerular filtration rate; IC, intermittent  claudication; PAD, peripheral arterial disease; SBP, systolic 
blood pressure. 
 
In PAD patients, higher values of NT-proBNP and hs-CRP were associated with higher 
incidence of CV events, whereas this was not the case for cystatin C. For NT-proBNP, the 
incidence of CV events was 64% vs. 15% (P < 0.001) in the high compared with the low 
tertile. For hs-CRP, the incidence  was 55% vs. 21% (P < 0.01)  and for cystatin C it was 
51% vs. 42% (P = 0.30) (Figure 3).  
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Figure 3. Incidence (%) of cardiovascular events in relation to tertiles of amino-terminal pro-B-type natriuretic peptide (NT-proBNP; low 
tertile: <97 ng/L; medium tertile: 97–319 ng/L; high tertile: >320 ng/L), high-sensitivity C-reactive protein (hs-CRP; low tertile: <1.7 
mg/L; medium tertile: 1.7–4 mg/L; high tertile: >4 mg/L), cystatin C (low tertile: <0.89 mg/L; medium tertile: 0.89–1.06 mg/L; high tertile 
>1.06 mg/L), and 24-hour pulse pressure (24-h PP; low tertile: <58.7 mm Hg; medium tertile: 59–69 mm Hg; high tertile: >69 mm Hg). 
Comparison with χ2 for NT-proBNP high vs. low tertile: P < 0.001. Comparison for hs-CRP high vs. low tertile: P < 0.01. Comparison for 
cystatin C high vs. low tertile: P = 0.30. Comparison for 24-h PP high vs. low tertile: P < 0.01. 
 
 
When used as continuous variables, 24-hour PP, log(NTproBNP),and log(hs-CRP) all 
predicted CV events in univariable analysis, whereas log(cystatin C) and centered quadratic 
term cystatin C did not. In multivariable analysis, log(NT-proBNP) and log(hs-CRP) still 
predicted CV events when adjusted for age, previous AMI, and treatment with BP-lowering 
drugs. Log(NT-proBNP) and log(hs-CRP) remained predictive for CV events when further 
adjusted for ambulatory blood pressure (Table 6). 
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Table 6  
Hazard ratio (HRs) and 95% confidence intervals (CIs) for cardiovascular events in peripheral artery disease patients, uni- 
and multivariate (n = 98) 
Predictor variables HR HR 95%CI P value 
Univariate    
24-h pulse pressure, per SD 1,63 (1.18–2.24) <0.01 
Log(NT-proBNP), per SD 2.12 (1.49–3.00) <0.001 
Log(hsCRP), per SD 1.61 (1.20–2.16) <0.01 
Log(cystatin C), per SD 1.26 (0.91–1.74) 0.16 
Centered quadratic term 
cystatin C 
1.54 (0.96–2.48) 0.07 
    
Multivariate adjusted for basic CV factors
a
   
24-h pulse pressure, per SD 1.44 (0.98–2.12) 0.06 
Log(NT-proBNP), per SD 1.68 (1.09–2.60) <0.05 
Log(hsCRP), per SD 1.53 (1.13–2.08) <0.01 
Centered quadratic term 
cystatin C 
1.27 (0.74–2.16) 0.39 
    
Multivariate adjusted for basic CV factors and ABP
b
.   
Log(NT-proBNP), per SD 1.62 (1.05–2.51) <0.05 
Log(hsCRP), per SD 1.63 (1.19–2.24) <0.01 
Centered quadratic term 
cystatin C 
1.32 1.32 1.32 
    
Abbreviations: 24-h, 24 hour; ABP, ambulatory blood pressure; AMI, acute myocardial infarction; BP, blood pressure; CV, 
cardiovascular;DBP, diastolic blood pressure; hs-CRP, high-sensitivity C-reactive protein; NT-proBNP, amino-terminal pro-B-
type natriuretic peptide; PAD,peripheral arterial disease; PP, pulse pressure; SBP, systolic blood pressure. 
a Basic CV risk factors: age, treatment with BP-lowering drugs, previous AMI. 
b Basic CV risk factors: age, treatment with BP-lowering drugs, previous AM and ABP. 
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5.3 STUDY III 
Overall, 12,313 individuals were available for analysis, whereof 4,794 were in complete twin 
pairs. For the GCTA 5,635 individuals were included. General characteristics of the overall 
study group are summarized in Table 7. The mean age was 64.9 years, 55% of the sample 
was female, and 7.8% had a history of cardiovascular disease prior to enrollment.  
 
Table 7  
General  Characteristics of Study Participants 
 All Men Women 
Total no of individuals
a
(n) 12313 5585 6728 
Complete pairs 4794 2133 2661 
MZ
b
(n) 3155 1353 1804 
OSDZ
c
(n) 4534 2191 2343 
SSDZ
d
(n) 4588 2018 2570 
UKZ
e
(n) 34 23 11 
Age(years) 64.9(±8.1) 65.2(±8.0) 64.6(±8.2) 
Weight (kg) 74.5(±13.9) 81.8(±12.3) 68.5(±12.1) 
Height (cm) 169.2(±9.2) 176.3(±6.9) 163.2(±6.2) 
Body Mass Index 26.0(±4.1) 26.3(±3.7) 25.7(±4.4) 
Current Smoker(n) 2021(16.4%) 866(15.5%) 1155(17.2%) 
Previous Smoker(n) 4870(39.6%) 2504(44.8%) 2366(35.2%) 
Never Smoker(n) 5335(43.3%) 2170(38.9%) 3165(47%) 
Diabetes 1202(9.8%) 687(12.3%) 515(7.7%) 
Hypertension
f
 5901(47.9%) 2799(50.1%) 3102(46.1%) 
Systolic Blood Pressure (mm Hg) 138.7(±19.7) 139.6(±19.3) 138(±20.0) 
Diastolic Blood Pressure (mm Hg) 81.9(±11.0) 83.1(±10.6) 80.9(±11.3) 
Pulse pressure (mm Hg) 56.8(±16.3) 56.5(±15.5) 57.1(±16.3) 
Hyperlipidemia
g
 9094(73.9%) 3654(65.4%) 5440(80.9%) 
Anti-hypertensive treatment 2675(21.7%) 1320(23.6%) 1355(20.1%) 
Statin treatment 1648(13.4%) 911(16.3%) 737(11%) 
CVD
g
 960(7.8%) 663(11.9%) 297(4.4%) 
Waist circumference (cm) 91.3(±12.2) 97.0(±10.2) 86.6(±11.6) 
Waist/Hip ratio 0.89(±0.13) 0.94(±0.13) 0.84(±0.11) 
Values are in means ± SD or percentage
  a
Number of individuals, 
b
Monozygotic, 
c
Opposite-sexed 
dizygotic, 
d
Same-sexed dizygotic, 
e
Unkonown Zygosity, 
f
Systolic Blood Pressure >140 mmHg and/or 
Diastolic Blood Pressure >90 mmHg, 
g
Cardiovascular Disease (Defined asICD10=I20.0,I21,I22,I63; 
ICD9=410,411B, 433,434; ICD8=410,411,432,433,434; Surgical codes=FNG02,FNG05,FNC,FND,FNE. 
diagnosed before study enrollment). 
g
Total cholesterol >5.0 mmol/L 
 
Mean cystatin C level was 1.02 mg/L and mean creatinine level was 77.5µmol/L. The 
estimates of GFR based on cystatin C were in general lower compared to estimates based on 
creatinine (Table 8). 
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The estimated heritability (h
2
) of cystatin C with the twin model was 0.55 (95% CI, 0.49-
0.60) in men, 0.63 (95% CI, 0.59-0.66) in women and 0.60 (0.56-0.63) for both sexes 
combined. For creatinine h
2
 was 0.56 (95%CI, 0.51-0.61) in men, 0.62 (95%CI, 0.58-0.65) in 
women and 0.59 (0.56-0.62) for both sexes combined. For these traits a dominant genetic 
component was significant. For the phenotypes derived from cystatin C and creatinine the 
dominance component was significant as well, whereas for CKD-epi estimated GFR and 
prevalent cardiovascular disease the correlation between MZ was less than twice the 
correlation for DZ and hence the ACE model was used. Effect of non-shared environment 
was significant for all phenotypic traits. The additive and dominant genetic variance 
components are presented in Table 9. 
 
Mean contact level was 3.01 for MZ twins while it was 2.59 for DZ twins (t test, p < .0001) 
Mean age at separation  20.0 years and 18.6 years for MZ and DZ respectively (t-test, p < 
.0001). None of these measures were significantly related to the absolute intra-pair difference 
in adjusted trait levels (data not shown). 
 
  
Table 8    
Clinical chemistry Characteristics of Study Participants 
 All Men Women 
N
a
 12313 5585 6728 
Glucose (mmol/L) 5.6(±1.2) 5.8(±1.3) 5.4(±1.1) 
Hba1c (%) 4.8(±0.7) 4.8(±0.7) 4.8(±0.6) 
LDL (mmol/L) 3.8(±1.0) 3.7(±1.0) 3.9(±1.0) 
HDL (mmol/L) 1.4(±0.4) 1.2(±0.3) 1.6(±0.4) 
Triglycerides (mmol/L) 1.3(±0.8) 1.4(±0.9) 1.3(±0.7) 
Total cholesterol (mmol/L) 5.8(±1.1) 5.5(±1.1) 6.0(±1.1) 
CRP(mg/L) 3.22(±6.5) 3.37(±7.6) 3.08(±5.0) 
Creatinine (µmol/L) 77.5(±23.6) 86.9(±28.8) 69.7(±14.2) 
Cystatin C (mg/L) 1.02(±0.3) 1.05(±0.3) 0.99(±0.3) 
Estimated GFR (MDRD)
a
 83.1(±18.1) 85.6(±19.8) 81.1(±16.2) 
eGFR CysC (ml/min/1,73 m2)
b
 83.6 (±21.9) 81.2(±21.8) 85.7(±21.6) 
CKD-epi Crea (ml/min/1,73 m2)
c
 86.1 (±16.0) 92.9 (±15.5) 80.4 (±14.0) 
CKD-epi CysC (ml/min/1,73 m2)
c
 76.4 (±19.5) 77.2(±20.2) 75.8 (±18.8) 
CKD-epi Crea+CysC (ml/min/1,73 m2)
c
 77.4 (±16.0) 76.8 (±16.2) 77.9 (±15.9) 
All values  are means ± Standard deviations. a GFR according to the MDRD formula. b Machine calculated GFR. c GFR according 
to the CKD-epi formula. 
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Through GCTA we found the estimate of the proportion of genetic variance to total 
phenotypic variance, V(g)/V(p), captured by all investigated markers to be significant for all 
traits (Table 10). GCTA heritability for cystatin C was 0.40 (SE 0.07, p 8e
-9
) and for 
creatinine 0.19 (SE 0.07, p 0.003). As there were sex-differences in heritability observed in 
the classical twin-model, we tested a GCTA model that included gene by sex interaction 
without finding any significant interaction term (p>0.05) for any of the 7 tested phenotypes.  
Table 10   
GCTA analysis 
Phenotype Source Variance SE P-value 
Cystatin C V genotypic (g) 0.404 0.0763  
V environmental (e) 0.608 0.0749  
V phenotypic (p) 1.012 0.0192  
V (g) / V (p) 0.399 0.0743 8e
-9 
     
Creatinine V genotypic (g) 0.190 0.0727  
V environmental (e) 0.798 0.0733  
V phenotypic (p) 0.988 0.0186  
V (g) / V (p) 0.192 0.0733 0.003 
     
eGFR(Cys C)
a
 V genotypic (g) 0.418 0.0766  
V environmental (e) 0.594 0.0751  
V phenotypic (p) 1.012 0.0192  
V (g) / V (p) 0.413 0.0644 3e
-9
 
     
MDRD(Crea)
b
 V genotypic (g) 0.186 0.0720  
V environmental (e) 0.791 0.0726  
V phenotypic (p) 0.977 0.0184  
V (g) / V (p) 0.191 0.0734 0.004 
     
Cdk-epi(Cys C+Crea)
c
 V genotypic (g) 0.192 0.0737  
V environmental (e) 0.821 0.0744  
V phenotypic (p) 1.013 0.0191  
V (g) / V (p) 0.190 0.0725 0.003 
     
Cdk-epi(Cys C)
c
 V genotypic (g) 0.247 0.0733  
V environmental (e) 0.769 0.0735  
V phenotypic (p) 1.016 0.0192  
V (g) / V (p) 0.243 0.0717 9e
-5 
     
Cdk-epi(Crea)
c
 V genotypic (g) 0.084 0.0707  
 V environmental (e) 0.918 0.0724  
 V phenotypic (p) 1.002 0.0189  
 V (g) / V (p) 0.084 0.0705 0.1 
All values adjusted for age, sex and correlated principal components.SE= Standard error, V=variance. a GFR according to the MDRD 
formula. b Machine calculated GFR. c GFR according to the CKD-epi formula. 
 
The results of the bivariate heritability analysis are shown in Table 11 . The phenotypic 
correlation between cystatin C and creatinine was estimated to 0.63 (95%CI, 0.61-0.65) in 
men and 0.55 (95%CI, 0.53-0.57) in women. The proportion of this correlation explained by 
additive genetic components (the bivariate heritability, (h2biv)) was 0.52 (95%CI, 0.44-0.59) 
in men and 0.51 (95% CI, 0.36-0.65) in women. For cystatin C vs CVD the correlation was 
 38 
0.16 (95% CI, 0.12-0.20) in men and 0.17 (95%CI, 0.13-0.21) in women and the genetic 
correlation in males was 0.41 (0.21-0.62) while it was non-significant in females. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.4 STUDY IV 
11402 participants were followed for a median time of 71 (SD±16) months, (general 
characteristics are shown in Table 12). 119 monozygotic and 155 same sexed dizygotic twin 
pairs, with no prevalent ASCVD at study enrollment, became discordant for incident 
ASCVD, stroke or MI during follow-up.  
  
Table 11  Bivariate Heritability analysis 
 Male Female 
Bivariate Correlations Cystatin C   vs   Creatinine 
Genetic (ra)  0.64 (0.58,0.70)   0.53 (0.43,0.62)  
Shared environmental (rc)  -0.99 (-1,1)   0.99 (-1,1)  
Non-shared environmental (re)  0.63 (0.58-0.67)   0.52 (0.47-0.57)  
 
Phenotypic correlation  0.63 (0.61,0.65)   0.55 (0.53,0.57)  
mediated by:  
Bivariate heritability (biv h
2
)  0.52 (0.44,0.59)   0.51 (0.36,0.65)  
Bivariate shared environment (biv c
2
)  0.00 (-0.02,0.04)   0.12 (-0.00,0.25)  
Bivariate non-shared environment 
(biv e
2
) 
 0.48 (0.41,0.56)   0.37 (0.32,0.42)  
  
Bivariate Correlations Cystatin C   vs   CVD 
Genetic (ra)  0.41 (0.21-0.62)   0.05 (-0.24, 0.43)  
Shared environmental (rc)  -0.99 (-1,1)   0.99 (-1,1)  
Non-shared environmental (re)  0.01 (-0.12, 0.13)   0.17 (0.06-0.28)  
 
Phenotypic correlation  0.16 (0.12-0.20)   0.17 (0.13-0.21)  
mediated by:  
Bivariate heritability (biv h
2
)  1.13 (0.59,1.72)   0.10 (-0.49,0.88)  
Bivariate shared environment (biv c
2
)  -0.15 (-0.49,0.17)   0.43 (-0.20,0.89)  
Bivariate non-shared environment 
(biv e
2
) 
 0.02 (-0.35, 0.39)   0.47 (0.17,0.77)  
  
Bivariate Correlations Creatinine   vs   CVD 
Genetic (ra)  0.32 (0.12-0.54)   -0.19 (-0.36,0.06)  
Shared environmental (rc)  -0.99 (-1,1)   0.43 (-0.38, 1)  
Non-shared environmental (re)  -0.11 (-0.23, 0.02)   0.09 (-0.33, 0.21)  
 
Phenotypic correlation  0.09 (0.05,0.13)   0.05 (0.01,0.09)  
mediated by:  
Bivariate heritability (biv h
2
)  1.64 (0.64,3.03)   -1.16*  
Bivariate shared environment (biv c
2
)  -0.09 (-0.79,0.55)   1.37*  
Bivariate non-shared environment 
(biv e
2
) 
 -0.55 (-1.50,0.08)   0.79*  
Cystatin C and creatinine are sex-, age adjusted and log-transformed.*There were some convergence 
problems when estimating the confidence interval for creatinine vs. CVD in females. 
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Table 12  
General  Characteristics of Study Participants   
  All Women Men 
Total number of individuals* (n)  
 
11402 6455(57%) 4947(43%) 
Complete Pairs 
 
4127 4781(58%) 3473(42%) 
Monozygotic Twins (n) 
 
2879 1680(58%) 1199(42%) 
Same Sex Dizygotic  Twins(n) 
 
4299 2511(58%) 1788(42%) 
Opposite Sex Dizygotic Twins(n) 
 
4194 2255(54%) 1939(46%) 
Unkonown zygosity (n) 
 
30 9(30%) 21(70%) 
Age (years) 
 
64.5(±8.0) 64.3(±8.1) 64.7(±7.9) 
Height(cm) 
 
169.1(±10.7) 163.2(±8.0) 176.4(±9.0) 
weight (Kg) 
 
74.2(±13.8) 68.5(±12.1) 81.7(±12.2) 
Body Mass Index (kg/m2) 
 
25.9(±4.1) 25.7(±4.4) 26.2(±3.7) 
Systolic Blood Pressure (mmHg) 
 
138.6(±19.7) 137.9(±20.0) 139.5(±19.2) 
Glucose mmol/L (serum) 
 
5.5(±1.1) 5.4(±1.0) 5.7(±1.3) 
HbA1c % (serum) 
 
4.8(±0.6) 4.8(±0.6) 4.8(±0.7) 
HDL Cholesterol mmol/L (serum) 
 
1.4(±0.4) 1.6(±0.4) 1.3(±0.3) 
LDL Cholesterol mmol/L (serum) 
 
3.8(±1.0) 3.9(±1.0) 3.8(±0.9) 
Total Cholesterol mmol/L (serum) 
 
5.9(±1.1) 6.0(±1.1) 5.6(±1.1) 
Cystatin C mg/L (Plasma) 
 
1.00(±0.25) 0.99(±0.23) 1.03(±0.27) 
Creatinine µmol/L (Plasma) 
 
76.5(±18.1) 69.5(±12.6) 85.8(±20.0) 
eGFR mL/min/1,73 m2 (CKD-epi)
†
 
 
86.3(±15.6) 80.7(±13.8)  93.6(±14.8) 
Current Smoker(n) 
 
1861(16%) 1098(17%) 763(15%) 
Anti-hypertensive tretment (n) 
 
2459(21.5%) 1426(22%) 1033(21%) 
Anti-lipids treatment (n) 
 
1046(9%) 582(9%) 464(9%) 
Diabetes
‡
 (n)  
 
933(8%) 421(6.5%) 512(10%) 
Values are in means ± SD or percentage  *Number of individuals, †Derived from the CDK-epi formula based on creatinine  
‡According to Swedish diabetes registry 
 
 
The results of Cox regression analysis in the whole cohort are shown in Table 13. In 
univariate analysis cystatin C was a predictor of incident stroke ((HR, 95% CI) 1.69, 1.56-
1.84) MI (1.49, 1.39-1.60) and ASCVD (1.57, 1.47-1.67). No association between MI and 
creatinine based CKD-epi was observed. When adjusted for all covariates including CKD-epi 
calculated eGFR(model 2, Table 13), cystatin C remained a predictor of incident stroke (1.45, 
1.25-1.70), MI (HR 1.16, CI 1.01-1.33) and ASCVD (1.26, 1.13-1.41)  
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A total of 116 monozygotic (MZ) and 155 same sexed dizygotic (DZ) twin pairs became 
discordant for incident ASCVD during follow-up.  In twins discordant for stroke, cystatin C 
was higher in diseased compared to healthy twins in both MZ (1.11 +/- 0.27 mg/L vs 1.06 +/- 
0.26 mg/L, p<0.05) and DZ pairs (1.2 +/- 0.37 mg/L vs 1.07 +/- 0.23 mg/L, p<0.01) whereas 
no difference was observed for creatinine (Table 14). DZ twins also showed significant intra-
pair difference in cystatin C levels with regard to discordance in the ASCVD endpoint (1.13 
+/- 0.31 mg/L vs 1.06 +/- 0.22 mg/L, p<0.02).   
  
Table 13 
Hazard ratios for incident ASCVD in unadjusted and adjusted cox prediction models in 11 402 twins 
 Univariate Adjusted Model 1
*
 Adjusted Model 2
†
 
Variable HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value 
Log Cystatin C       
Stroke 1.69 (1.56-1.84) <.001 1.31(1.17-1.46) <.001 1.45 (1.25-1.70) <.001 
    MI 1.49 (1.39-1.60) <.001 1.11 (1.00-1.24)   .05 1.16 (1.01-1.33)   .04 
ASCVD 1.57 (1.47-1.67) <.001 1.19(1.10-1.29) <.001 1.26 (1.13-1.41) <.001 
CDK-epi (crea)       
Stroke 0.78(0.69-0.87) <.001 0.90 (0.80-1.03) .13   
    MI 0.94 (0.85-1.04) .25 0.96 (0.86-1.08) .54   
ASCVD 0.99 (0.99-1.00) <.001 0.94 (0.86-1.03) .17   
Age       
Stroke     1.11 (1.09-1.12) <.001     
MI     1.07 (1.06-1.08) <.001     
    ASCVD 1.09 (1.08-1.10) <.001     
Sex       
Stroke 0.51 (0.41-0.63) <.001     
MI 0.38 (0.31-0.46) <.001     
ASCVD 0.44 (0.37-0.51) <.001     
Smoke       
Stroke 1.03 (.96-1.12) .39     
MI 1.10 (1.03-1.18) .003     
ASCVD 1.07 (1.10-1.31) .006     
HDL       
Stroke 0.67 (0.51-0.89) .006     
MI 0.33 (0.26-0.43) <.001     
ASCVD 0.48 (0.39-0.59) <.001     
Total Cholesterol       
Stroke 0.91 (0.82-1.02) 0.09     
MI 1.01 (0.92-1.12) 0.81     
ASCVD 0.98 (0.91-1.06) 0.60     
Anti-HT treat       
Stroke 0.91 (0.82-1.02) 0.09     
MI 1.01 (0.92-1.12) 0.81     
ASCVD 0.98 (0.91-1.06) 0.60     
Diabetes       
Stroke 0.91 (0.82-1.02) 0.09     
MI 1.01 (0.92-1.12) 0.81     
ASCVD 0.98 (0.91-1.06) 0.60     
*Adjusted model 1 includes age, sex, SBP, serum cholesterol, HDL, treatment for hypertension (yes/no), diabetes (yes/no),) and smoking 
status (yes/no),   
†Adjusted model 2 includes age, sex, SBP, serum cholesterol, HDL,  treatment for hypertension (yes/no), diabetes (yes/no),  smoking status 
(yes/no) and eGFR(CKD-epi)   
 
  41 
The results of conditional regression analysis in pairs discordant for incident ASCVD are 
shown in Table 15.  When adjusted for the same covariates as in the cox regression model 
and stratified by zygosity cystatin C did not remain significantly associated with any 
outcome. In univariate analysis cystatin C was significantly associated with stroke and 
ASCVD but not MI in same sexed dizygotic twins. Univariate analysis of cystatin C in MZ 
did not reach significance level (p=0.052). However in multivariate analysis of cystatin C and 
eGFR cystatin C was significantly associated with incident stroke in MZ, although the 
confidence interval was quite broad.  
Table 14  
Paired T-tests in twin-pairs discordant for stroke, ASCVD and MI 
Stroke 
 MZ (n=59)   DZ (n=79)  
Variable Sick Healthy p-value Sick healthy p-value 
       Cystatin C 1.11+/-0.27 1.06+/-0.26 0.0439 1.20+/-0.37 1.07+/-0.23 0.0015 
Creatinine 76.12+/-16.87 79.39+/-20.32 0.1288 85.05+/-20.19 81.16+/-13.42 0.1411 
CKD-EPI 85.56+/-17.32 83.51+/-16.91 0.1902 82.52+/-16.32 79.73+/-18.15 0.1235 
HDL 1.40+/-0.48 1.34+/-0.35 0.1431 1.36+/-0.38 1.43+/-0.42 0.1377 
Total Cholesterol 5.98+/-1.30 5.77+/-1.26 0.2675 5.90+/-1.29 5.91+/-1.37 0.9454 
BMI  * 
†
 26.66+/-3.93 26.09+/-4.49 0.1487 25.84+/-3.86 25.58+/-3.75 0.5813 
SBP 
‡
 
§
 149.2+/-21.92 146.1+/-20.22 0.5433 151.6+/-25.79 147.0+/-21.32 0.1280 
*MZ(n=54) †DZ(n=75) ‡MZ(n=52)  §DZ(n=74)     
     
MI 
 MZ (n=71)   DZ (n=84)   
Variable Sick Healthy p-value Sick healthy p-value 
       
Cystatin C 1.06+/-0.22 1.06+/-0.22 0.9359 1.11+/-0.32 1.08+/-0.24 0.5786 
Creatinine 77.28+/-16.86 79.97+/-18.32 0.1273 81.66+/-16.32 80.57+/-16.98 0.5189 
CKD-EPI 86.02+/-16.03 83.42+/-15.88 0.1309 84.38+/-16.52 83.55+/-16.69 0.6463 
HDL 1.29+/-0.35 1.30+/-0.38 0.7270 1.30+/-0.38 1.38+/-0.38 0.0973 
Total Cholesterol 5.78+/-1.06 5.62+/-1.06 0.3142 6.11+/-1.22 5.92+/-0.99 0.2587 
BMI  * 
†
 26.13+/-3.83 26.56+/-3.84 0.1818 26.51+/-3.86 25.82+/-4.05 0.1858 
SBP * ^ 143.3+/-20.27 149.0+/-19.68 0.0481 147.6+/-23.98 146.2+/-20.63 0.7143 
*MZ(n=61) †DZ(n=77)  ‡MZ(n=67) §DZ(n=80)     
     
CVD 
 MZ (n=116)   DZ (n=149)   
Variable Sick Healthy p-value Sick healthy p-value 
       
Cystatin C 1.08+/-0.25 1.07+/-0.24 0.3332 1.13+/-0.31 1.06+/-0.22 0.0182 
Creatinine 76.71+/-16.72 80.11+/-19.43 0.0210 81.66+/-18.46 80.68+/-15.58 0.7129 
CKD-EPI 85.86+/-16.63 83.19+/-16.37 0.0310 82.70+/-16.78 84.31+/-19.45 0.5561 
HDL 1.33+/-0.36 1.31+/-0.30 0.3263 1.33+/-0.34 1.40+/-0.39 0.0502 
Total Cholesterol 5.92+/-1.16 5.69+/-1.14 0.0692 5.98+/-1.25 5.88+/-1.18 0.4428 
BMI  * 
†
 26.45+/-4.21 26.46+/-3.93 0.8910 26.08+/-3.58 25.69+/-3.82 0.3010 
SBP * 
†
 146.6+/-21.19 148.5+/-19.74 0.4118 147.6+/-23.98 146.2+/-20.63 0.3276 
*MZ(n=107) †DZ(n=139)      
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Data on contact frequency by at least one of the twins in a pair was available for 11040 (97%) 
of the study participants. The intra pair correlation on contact frequency was high (rho=0.80) 
for the 3954 pairs where both responded. Data on age at separation was available for 11145 
(98%) individuals, correlation was somewhat lower compared to contact frequency, 
(rho=0.65) for 3206 responding pairs. MZ twins reported a higher contact frequency and 
higher mean age at separation than DZ twins. Mean contact level was 3.02 (SD+/-0.86) for 
MZ twins while it was 2.72 (SD+/-0.84) for DZ twins (t test, p < .0001). Mean age at 
separation 19.49 (SD+/-3.38) years and 18.45 (SD+/-3.48) years for MZ and DZ respectively 
(t-test, p < .0001). None of these measures were significantly related to the absolute intra-pair 
difference in adjusted trait levels in MZ, but contact level was related to intra-pair difference 
in cystatin C levels in DZ (Table 16).  
Table 16  
Correlation Between Absolute Intra-Pair Difference of Adjusted Trait Values and (A) Co-Twin Contact Frequency and 
(B) Age at Separation From Co-Twin 
Phenotype  MZ
†
   ssDZ
‡
  
 r
*
 p-value N(pairs) r
*
 p-value N(pairs) 
(A) Contact frequency       
Cystatin C    -.04 .16 1173   -.06 .03 1527 
CKD-epi    -.01 .65 1165   -.03 .22 1530 
       
(B) Age at Separation       
Cystatin C    -.01 .70 1177  -.03 .25 1495 
CKD-epi    -.01 .65 1116    -.003 .90 1499 
       
*Spearman correlation coefficient, Note:  p-values remained unsignificant for opposite sex dizygotic when stratified by sex 
†Monozygotic twins 
‡Same Sex Dizygotic twins 
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6 DISCUSSION 
The main purpose of this thesis was to study the association between cystatin C and 
atherosclerotic cardiovascular disease with a special focus on the relative importance of 
genetics and environment. In paper I, we observed that the mean serum level of cystatin C-
was higher in PAD patients compared with healthy controls even when corrected for 
differences in eGFR, IL-6 and CRP. In a follow-up, cystatin C was not a significant predictor 
of incident cardiovascular events in patients with manifest PAD, although we observed a U-
shaped relation between tertiles of cystatin C-concentration and outcome. 
In a large twin study we observed a higher heritability of cystatin C compared with previous 
studies on the matter. The GCTA analysis provided independent evidence for significant 
heritability indicated by the twin-model.  We also observed a significant genetic correlation 
between levels of cystatin C and creatinine as well as a genetic correlation between levels of 
cystatin C and CVD in males indicating an overlap of the genetic factors that influence the 
two traits in males. In a prospective study in the same population we showed that cystatin C 
was a predictor for incident ASCVD, confirming previous studies. A novel finding was that 
cystatin C remained a predictor for incident stroke after adjustment for genetic confounding, 
in identical twins discordant for incident stroke, highlighting the importance of unique 
environmental factors for the association between cystatin C and ASCVD.   
6.1 CYSTATIN C AND THE ASSOCIATION TO PAD 
In our first study we observed a higher mean level of cystatin C in PAD patients compared 
with a matched control group. The major underlying cause of PAD, atherosclerosis, is an 
inflammatory disease of the cardiovascular system, which is characterized by extensive 
remodeling of the extracellular matrix of the arterial wall. During this process several 
pathological events take place, such as proteolysis, translocation of leukocytes through the 
basement membrane, migration of smooth muscle cells through the elastic laminas, and 
finally, disruption of the vessel wall into aneurysms or occlusive plaques.
168
 These 
processes create a local inflammatory response with the activation of growth factors and 
cytokines, of which IL-6 is of major importance as a mediator of the inflammatory 
process.
169
 It has been implicated that an imbalance between the expression of cathepsines 
and their endogenous inhibitor cystatin C is another important mechanism in 
atherogenesis.
170
 In contrast to the findings for cystatin C we observed no significant 
difference in eGFR estimated by MDRD or calculated creatinine clearance between patients 
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and controls. This is in agreement with the fact that creatinine is a rather insensitive GFR 
marker.
64,67,171
 In an analysis of covariance where either eGFR or calculated creatinine 
clearance was added as a covariate, cystatin C concentration remained higher in the PAD-
group. Thus, our results indicated that the increase in cystatin C concentration seen in PAD-
patients might not be related solely to a concomitant decline of kidney function. One 
hypothesis is that the increased cystatin C concentration may be related to a more advanced 
stage of atherosclerosis and therefore we also adjusted for inflammatory markers related to 
atherosclerosis. We found that the increased level of cystatin C in PAD patients persisted 
when either IL-6 or CRP levels were added as covariates in a multivariate model, lending 
further support to the hypothesis that cystatin C could be used as an independent marker of 
atherosclerotic disease. Cystatin C-concentration correlated to IL-6 and CRP concentrations 
in PAD-patients but variation in IL-6 levels or CRP could not explain all of the increased 
concentration of cystatin C seen in PAD-patients. Thus, it seems that the observed increase 
in cystatin C-concentration could reflect other mechanisms in the atherosclerotic process 
than markers of inflammation such as CRP and IL-6 do. Such possible mechanisms may 
include, atherosclerotic vascular wall remodeling by collagenolysis and elstinolysis or a 
more rapid progression of vascular ageing.  
6.2 PREDICTIVE VALUE OF CYSTATIN C IN PAD 
In paper II we studied the predictive value of cystatin C in PAD-patients. The main findings 
was that cystatin C was not a predictor of a combined endpoint consisting of mortality or 
any hospitalization due to acute myocardial infarction , stroke or coronary revascularization 
percutaneous coronary intervention or coronary artery by-pass graft. Our findings are in 
contrast to the results from a longitudinal study in a somewhat bigger cohort, but with 
comparable baseline characteristics as ours, which suggested that cystatin C was a predictor 
of 5-year cardiovascular mortality independent of renal function in PAD patients.
171
 
Although the different findings in the two studies are surprising one possible explanation 
may be that different outcomes were studied. Besides the study by Urbonaviciene et al, there 
are very few studies regarding the prospective relationship between cystatin C and CVD in 
patients with PAD. Both Koenig et al and Ix et al have previously reported a predictive value 
of cystatin C in populations with general atherosclerotic cardiovascular disease.
6,172
 
Admittedly, the last mentioned prospective studies were partly different from ours both in 
terms of study size and study population. The Ix-cohort consisted of individuals with stable 
coronary heart disease defined as history of MI, angiographic coronary stenosis, stress-
induced myocardial ischemia or a history of coronary revascularization, while the Koenig-
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cohort consisted of persons with prevalent coronary heart disease. Regarding the endpoints, 
the Ix-endpoint was all-cause mortality, cardiovascular events (AMI and stroke) and incident 
heart failure, while Koenig’s was more similar to ours with CVD death or non-fatal MI or 
ischemic cerebrovascular event. Nevertheless, peripheral arterial disease is a manifestation of 
general atherosclerotic disease that is often silent and thus underdiagnosed even in patients 
with manifest ischemic heart disease.
173,174
 Hence it is not farfetched to draw the conclusion 
that a considerable comorbidity might be present and thus the patients in the Ix and Koenig 
studies might very well have suffered from concomitant asymptomatic undiagnosed 
peripheral atherosclerosis.  
 
A plausible explanation to the result in our study is the small size of the cohort and the rather 
few events which might give rise to a type 2 error, however for other biomarkers as well as 
ambulatory blood pressure, we could report highly significant associations to the outcome .  
Lastly, the finding of an U-shaped relation between tertiles of cystatin C concentration and 
outcome (Figure 3) was not anticipated, because of this a quadratic model was also used 
without any change of significance of the result. The U-shaped relation between cystatin C 
concentration and a second cardiovascular event in PAD-patients is an interesting finding 
that, to our knowledge, has not been reported before. A U-shaped association has been 
described between cystatin C and incident cognitive imparment/dementia in a longitudinal 
study in a population based cohort of elderly women.
175
 A similar U-shaped association has 
also been reported between creatinine, but not cystatin C, and subclinical brain infarction in a 
cross-sectional study in a community based cohort of men and women > 65 years of age.
176
 A 
third study noticed the same pattern between creatinine, but not cystatin C, and inflammatory 
markers (CRP and fibrinogen) in a cross-sectional study in a community based cohort of men 
and women with mean age of 75.
177
 An interpretation of this might be that cystatin C may 
reflect different activities in different stages of an ongoing atherosclerotic process, such as 
inflammation and small vessel degeneration leading to end organ damage such as subclinical 
brain infarction and subsequent vascular dementia. As mentioned earlier cystatin C is an 
inhibitor of cathepsins,
168
 with regards to that a somewhat more speculative interpretation of 
the U-formed shape could be that it reflects an initial depletion of cystatin C in response due 
to increased extracellular matrix degradation and vascular wall remodeling such as seen in 
atherosclerosis and abdominal aortic aneurysms.
178,179
 A reciprocal upregulation may in the 
early phases not be fast enough to counterbalance the pathogenic mechanisms such as 
inflammation,
180,181
 thus leading to increased events in the low tertile. In the high tertile the 
increased events may simply be due to the fact that cystatin C’s inhibitory effect is not 
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efficient enough in this late stage of disease. In our fourth paper we found a connection 
between cystatin C and incident stroke and AMI, however this association was not U-shaped.   
6.3 HERITABILITY OF THE ASSOCIATION BETWEEN CYSTATIN C & CVD 
The results of our first study indicate an unambiguous connection between cystatin C and 
atherosclerotic cardiovascular disease. Whether this was due to a causal association, or if it 
merely owed up to proxy effects of impaired renal function in atherosclerotic patients is 
unclear. Further, we were not able to establish a predictive effect of cystatin C with regards to 
future cardiovascular events in an already atherosclerotically burdened cohort. This might 
solely be due to power issues as there are numerous studies that have proved that cystatin C is 
significantly associated with, and predictive of incident CVD,
171,182,183
 however few studies 
exist in patients with manifest CVD. Thus it prompted us to further investigate the relation 
between cystatin C and atherosclerotic CVD in a considerably larger cohort.  
Since atherosclerosis is considered a genetically complex disease we decided to investigate 
the importance of heritage and environment for the connection between cystatin C and 
prevalent as well as incident ASCVD. By using the classic twin model we estimated the 
heritability of both cystatin C and creatinine to just under 0.6 on average for both sexes. For 
cystatin C the estimate is higher than what has been found in a previous study that used an 
extended pedigree model, where the heritability was estimated to be 0.40 when adjusted for 
age and sex, and attenuated to 0.35 upon further multivariable adjustment.
184
 The study by 
Parikh et al. differs from ours regarding methodology, size and age of the participants, 
therefore results may not be fully comparable. For serum creatinine, previous studies have 
reported heritabilities in the range of 0.00-0.64,
185-188
 whereas the heritability of creatinine-
based estimated GFR was 0.31-0.63. 
188,189
  Our heritability estimate for creatinine in is 
similar to that found by Jermendy et al,
186
 but higher compared to what is described by 
Nilsson et al.
187
  In accordance to our results, Nilsson et al found that the genetic influence 
was higher in women than in men, although under an ACE-model. In a Danish population-
based twin study no heritability at all was found in men but a substantial dominance 
component in women.
190
 However, the study cohorts in all these studies were five to tenfold 
smaller than ours, and the Jermendy cohort is also substantially younger, why comparisons 
need to be made with some caution. Further, we saw significant differences between the 
sexes both in terms of heritability and the proportion of the variance explained by additive 
and dominance genetic factors respectively. In women the broad sense heritability, here 
consisting of additive  and dominance components contributing to the variance (Table 9), was 
larger than in men, which for creatinine is consistent with earlier findings.
187
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The finding of a dominance effect for cystatin C is, to our knowledge, new. In previous twin 
studies the ACE model has been preferred, whereas in ours the ADE model was preferred for 
four out of seven investigated traits. A reason for this might be the large study population 
which enhances power and enables detection of weaker variance components underlying the 
traits. Another contributing factor may be the relatively high age of the participants which 
might possibly lead to decreased influences from shared familial environment.  
The most striking sex difference in our findings was also related to the dominance 
component. In men the dominance component was about the same size as the additive 
component whereas in women the dominance component was almost absent. Thus our 
findings possibly reflect an x-linked component,
191
 or a gene-gene interaction specific to 
men. For the phenotypes in our investigations where the ACE-model was preferred (CKD-epi 
formula derived GFR and CVD) heritability was higher in men, but the common environment 
component was significantly larger in women.  
 
The reported “chip heritability” V(g)/V(p) from the GCTA analysis in our cohort was 0.40 
for cystatin C and 0.19 for creatinine. Previous studies using the GCTA method for various 
traits and diseases has found that the “chip heritability” tends to be in the order of ¼ to ½ of 
the twin-based heritability.
192
 Here, we found the V(g)/V(p) to approach 65% of the twin-
based sex averaged estimate for cystatin C and cystatin C based machine estimate of GFR, 
but only about 30% for creatinine and MDRD, which indicates that an unusually large 
proportion of the genetic variability for cystatin C appears to be captured by the investigated 
common SNP markers.  
 
The definition of cardiovascular disease we have utilized is a commonly used endpoint in 
cardiovascular interventional studies and in epidemiological cohort studies. However, to our 
knowledge no previous study has reported heritability for this combined phenotype. The 
heritability of 0.39 respectively 0.20 in men and women for CVD that we report may be 
compared to a heritability of 0.57 in men and 0.38 in women for death by coronary heart 
disease reported by  Zdravkovic  et al.
193
 When we divided CVD into its components 
coronary artery disease and stroke, the heritability for CAD increased to 0.48 in men and 0.30 
in women. These differences may in part be explained by the fact that the Zdravkovic study 
only studied mortality from coronary heart disease, in which genes might be more apparent 
than for other manifestations. Due to a larger number of outcomes the power to assess 
heritability in the Zdravkovic study was better than in our cohort. Further, it may be more 
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difficult to delineate the role of genetic effects for composite endpoints such as CVD as risk 
factor patterns for the included endpoints may differ.  
6.4 PREDICTIVE VALUE OF CYSTATIN C FOR INCIDENT ASCVD 
The observation that common genetics appear to mediate phenotypic correlation between 
cystatin C and prevalent cardiovascular disease led us to further investigate the relative 
importance of gene and environment for the association to incident ASCVD as well. The 
association of cystatin C and creatinine-based eGFR to incident ASCVD was thus studied in 
a prospective co-twin control design. We showed that variation in cystatin C related to 
incident ASCVD independent of traditional risk factors and creatinine based eGFR, thus 
confirming earlier studies.
194-196
 A novel finding was that cystatin C predicted incident stroke 
in MZ twins adjusted for genetic confounding. 
 
The finding that cystatin C is superior to creatinine for prediction of incident ASCVD 
confirms findings from previous population-based studies,
101-103
 but is for the first time 
observed in a twin-cohort. Besides being somewhat larger compared to the study by 
Svensson-Färbom the fact that our cohort consisted of twins allowed us to control for genetic 
confounding. We also stratified our combined endpoint into MI and stroke and were thus able 
to see a difference in the association of cystatin C with regards to these two endpoints. It is 
plausible that it primarily is a reflection of cystatin C being a better marker of early 
hypertensive end organ damage in different vascular beds. That is – a more sensitive marker 
of early GFR-reduction.  In this regard cystatin C might be a marker of early vascular ageing, 
and as such detect subclinical manifestation of features such as small vessel degeneration, left 
ventricular heart load, arterial calcification and matrix remodeling and intima 
alterations.
105,106
 
 
The finding that cystatin C is related to incident stroke in identical twins is a novel finding 
which indicates that individual specific (i.e. non-shared within pairs) environmental factors 
that affect cystatin C also associates to incident stroke. This is further supported by the 
finding that the intra-pair contact frequency and age at separation was not significantly 
associated with trait-level similarity in MZ twins (Table 16). Based on the findings and study 
design it cannot be concluded what constitutes these unique environmental factors.  
Previously reported environmental factors that are associated to cystatin C or mild eGFR-
reduction are smoking and occupational exposure to lead and arsenic.
197-200
  It could be 
exposure to some other external factor whose connection to cystatin C and ASCVD yet 
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remains to be discovered. When we adjusted for traditional risk factors such as serum 
cholesterol, lipids, diabetes, anti-hypertensive treatment, systolic blood pressure, smoking 
and decreased kidney function this association remained which indicates that the external 
factor is independent of them.  Our findings are in agreement with recently published 
Mendelian randomization studies
201
 which have reported negative results on the association 
between SNP:s related to cystatin C and incident CVD. Therefore environmental factors are 
indeed the most likely cause of the association between cystatin C and incident ASCVD and 
may also be possible to prevent if identified.  
6.5 GENETIC CORRELATION OF VARIATION IN CYSTATIN C AND 
CREATININE WITH PREVALENT AND INCIDENT ATHEROSCLEROTIC 
CARDIOVASCULAR DISEASE 
We found a significant genetic correlation between levels of cystatin C and creatinine.  This 
correlation was explained by shared genetic- and non-shared environment to approximately 
the same extent.  Since the variations in both phenotypes reflect renal function, renal function 
is probably more strongly related to the covariance of the two traits than to the individual 
phenotypes. The observation that shared genes contributed substantially to the covariance of 
the two traits, and thus renal function, is an expected finding, while the small contribution of 
shared environment is not. The most common risk factors related to chronic kidney disease 
are overweight, hypertension and diabetes mellitus,
202
 where genes as well as environmental 
factors are important in all three.   In our study population very few had verified CKD and the 
majority of the variation of the studied phenotypes was in the normal GFR range. The 
contribution of these classic risk factors to the variation of the studied phenotypes in the 
normal range is unknown. Further, we observed genetic correlation between CVD and 
cystatin C despite a low phenotypic correlation between the traits, which also is a novel 
finding. The relation between creatinine and CVD was similar but the phenotypic correlation 
between these two traits was very weak. Although the variation in cystatin C only explained a 
small part of the variation in CVD, the covariance between the traits was entirely explained 
by common genes. This finding was only significant in males and may reflect that CVD was 
more common in men and thus a low power in the study to detect possible associations in 
women. It is possible that the shared genetic factor may affect all these phenotypes directly.  
However, the finding that cystatin C and CVD partly share common genes may also indicate 
a possible causal relation between cystatin C and CVD.  
 
Previous studies have reported about genetic overlap between kidney function and 
ASCVD.
203
 Although these overlaps were quite modest, ranging from 0.1 to 0.26 % and 
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associated with different stroke sub-types, they confirm earlier epidemiological studies on the 
matter suggesting such genetic overlaps.
204
 While both creatinine and cystatin C based kidney 
function was used in the study by Holliday et al, creatinine was more commonly used, and 
since cystatin C is superior for risk prediction - further investigations on the possible genetic 
overlap between stroke and cystatin C was warranted. We observed a stronger association 
between cystatin C and incident stroke compared to incident MI. Svensson-Färbom were able 
to demonstrate a significant association between cystatin C and ASCVD morbidity that was 
not present for creatinine based eGFR until eGFR was below 45mL/min, corresponding to 
less than 1% of the study population. However they did not study the associations to MI and 
stroke separately. A plausible explanation, especially if we assume that cystatin C is a marker 
of small vessel disease and hypertensive end organ damage, is that in normal kidney function 
cystatin C captures the risk of ASCVD trough small vessel disease but when renal function 
declines this discrimination gets distorted and cystatin C instead captures the risk of ASCVD 
due to renal dysfunction.  
 
We observed that non-shared environment might mediate intra-pair discordance regarding 
stroke incidence. This finding is in accordance to results from previous studies that have 
shown that only a small fraction of stroke variance is explained by genetic overlap with renal 
function estimates.
205
 Further support for the small genetic overlap between these traits can be 
found in a study by Olden et al,
206
 where SNPs associated with CKD were tested for 
association with CVD traits and vice versa. The result from this study concludes that there is 
little overlap between kidney and cardiovascular disease risk variants in the overall 
population and that non-genetic, i.e. environmental, factors in the causal pathway are 
responsible for the major part of the association between ASCVD and kidney function. 
Therefore, it is important to further investigate the part of the association that is related to 
environment and unarguable also better suited as a target for preventive measures.  
 
The finding that cystatin C and CVD partly share common genes may indicate a possible 
causal relation between cystatin C and CVD. However this association is between prevalent 
CVD and cystatin C and hence it is not possible to draw any conclusions regarding a potential 
causal relationship. The association may very well be due to reversed causality, i.e. CVD in 
itself may have caused the elevations in cystatin C. It is also possible that the link is due to 
confounders that are linked to both exposure and outcome. In the longitudinal design of study 
IV, the time factor makes associations between exposure and outcome more straight forward 
as the exposure precedes the outcome. Still this is not evidence of causality, even when 
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adjusting for confounders, as confounding factors may be unknown or masked. However 
reversed causality is less likely and thus our findings may indicate that this is not the case 
regarding the association between cystatin C and CVD. 
 
We do indeed present results indicating a genetic overlap between cystatin C and prevalent 
CVD in our studies which may indicate causal associations. This reasoning has made the 
relation between cystatin C and CVD suitable for Mendelian randomization studies (MR) in 
which firstly an instrumental variable that is related to the variance of the studied risk factor 
is identified (one or several SNP:s from the genome) and secondly the relation of this 
instrumental variable to the occurrence of the disease in question is studied.
136
 MRs uses the 
unique properties of the genome, to investigate causality of a biomarker. The unchangeable 
nature of the genome and Mendel’s laws of random distribution of alleles from parents to 
offspring at conception, means that genetic information is not influenced by disease status 
(reverse causality) or traditional risk factors (confounding).
130
 Thus, genetic variation that 
controls serum concentrations of cystatin C could be used as a variable to assess the effect of 
elevated concentrations of cystatin C on disease risk, independent of potential confounders. 
This has recently been done, and findings from  this recently performed  Mendelian 
randomization (MR) study contradicts a causal relation of cystatin C with regards to coronary 
artery disease.
201
 This has also been confirmed and extended to stroke, heart failure, diabetes 
and the metabolic syndrome in two other well powered MR-studies, yet only published as 
abstracts.
207,208
 Thus a more plausible reason to the genetic overlap between cystatin C and 
CVD in our studies is, given these findings, that it is due to pleiotropy where the same genes 
affect both phenotypes independently. Further cystatin C is a marker of chronic kidney 
disease, which in part in itself is a form of vascular disease, such as atherosclerotic 
renovascular disease (ARVD),
209
 which makes studies of and conclusions regarding causality 
utterly complex. Thus it is also possible that the seemingly independent correlation between 
cystatin C and PAD in our studies is due to subclinical renal failure, possibly on the basis of 
ARVD, that creatinine based eGFR is unable to detect. 
6.6 METHODS DISCUSSION 
Analysis of covariance, ANCOVA is a strong method for comparing the means of a 
continuous dependent variable between two or more groups with regards to levels of an 
independent categorical variable while controlling for a the effects of a third continuous 
variable. This method was successfully applied in order to analyze the separate effect of PAD 
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on serum cystatin C-levels and the possible interaction between PAD and renal impairment in 
study I. 
 
Survival analysis using Cox-regression is a useful method to estimate the association between 
a risk factor and time to an event. It is most often applied in order to study the relationship 
between exposures and a dichotomous outcome variable such as death, onset of disease etc. 
Study subjects are followed from baseline until they reach either the endpoint or a censoring 
endpoint (for example death from other causes than the studied). The result is expressed as 
hazard ratios reflecting the risk of an event anytime during the study period compared to an 
unexposed control group. It is also possible to add multiple covariates to test for interaction, 
as was done in the analysis of cystatin Cs predictive value in study II and IV.  
 
Logistic regression is a statistical model that is used to describe the association between one 
or several continuous or dichotomous exposure variables and one dichotomous outcome 
variable. This is a useful method for assessing the effect of different exposures with regards 
to an outcome, such as was done in study IV where monozygotic and dizygotic pairs 
discordant for ASCVD were compared. 
6.6.1 GCTA & Twin model 
Since the GCTA and twin model represent two different methods of estimating heritability, 
the two methods should be regarded as complementary rather than directly comparable. One 
of the major differences between the methods, which also likely explain the difference in the 
twin study estimates compared to the GCTA-estimates, is that the GCTA only estimates 
genetic variability captured by the SNP markers. Non-tagged polymorphism such as rarer 
single base-pair mutations, copy number variations and rare alleles, which will affect the 
estimate in the twin based model, will not contribute to the GCTA. Further, the GCTA model 
assumes additive genetic variance and thus only captures the narrow-sense heritability, i.e. 
non-additive effects such as dominance, gene-gene interactions (epistasis) and gene-
environment interactions are not accounted for. There is also a possibility that the estimates 
of the twin-model are inflated by a violation of one or more of the general assumptions of 
equally shared environment, minimal gene-environment interaction, random mating or 
generalizability to the population, which might further widen the gap between the heritability 
estimates derived from the two models. The equally shared environment assumption 
stipulates that monozygotic and dizygotic twins are exposed to trait-relevant shared-
environmental influences equally. A violation of the equal environment assumption would be 
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if MZ twins share more raising environment than do DZ. This would lead to an increased MZ 
correlation relative to DZ correlation, which would mimic genetic dominance effects and 
result in an overestimation of the dominance genetic effect relative to the shared 
environmental effect. A violation of the minimal gene-environment interactions assumption 
on the other hand where different genotypes responds differently to the same environment 
could instead lead to an inflation of the unique environment effect.  
6.7 LIMITATIONS 
As is the case with observational studies in general, all papers in this thesis are possibly 
limited by a range of different biases, ranging from selection bias due to self-selection, 
through misclassification of subjects regarding exposure as well as endpoint, to recall bias 
due to the fact that some of the data used stems from interviews and participation forms.   
6.7.1 Study I & II 
As pointed out earlier, our study population was quite small, which limits the power of the 
studies. Further the study population consisted of men only which limits the findings with 
regard to gender, although it increases the homogeneity of the study. The case–control  
design of study I also precludes us from drawing conclusions about causal mechanisms. 
Another limitation of our study is that we used the MDRD equation to calculate GFR instead 
of directly measuring for example iohexol clearance. Morbidity and mortality data were 
acquired from the Swedish National Board of Health and Welfare, and these data are based 
on hospital records from treating physicians, which might be associated with ascertainment 
biases. To limit the risk of misdiagnosis, we have reviewed the hospital records to validate 
the diagnosis of hospitalization and causes of mortality.  
6.7.2 Study III & IV 
A well-known limitation of twin studies is that it is not possible to incorporate the effect of 
shared environment and dominance genetics simultaneous, therefore both factors may co-
exist but not be detectable in the same model. Similarly the estimated effect from 
additive/dominance genetic effects may potentially arise from epistasis or gene-
environment interactions, why all results on additive and dominance genetics could be 
biased. Moreover, the fact that the classic twin design relies on four general assumptions 
makes it vulnerable, especially with regards to the assumption of equal environment 
influences between MZ and DZ which may result in an overestimation of the genetic effect 
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and an underestimation of the shared environmental effect. Still, in order for an equal 
environments assumption violation to be a major problem there must be an association 
between degree of shared environment and trait similarity. Further, variance components 
estimates are study population-specific, meaning that they might not be representative for 
other populations or ethnic groups. Since both genetic and environmental factors may be 
explicit to the studied population it may be these factors that drive the difference between 
studies. Since our cohort consists mainly of elderly individuals the common environment 
factor may be less prominent than in a younger population, and thus make generalizability 
lower.  
 
A limitation of the genome wide complex trait analysis is that it can only detect the additive 
effects of the common SNPs (i.e. with allele frequencies greater than 1%) that are 
incorporated in the DNA microarrays used in genome-wide association studies  and not non-
additive effects such as gene-gene or gene-environment interactions. 
210
 Further, GCTA 
estimates are the result of using only SNPs but there are numerous other kinds of prevalent 
genetic polymorphisms, such as copy number variations, multiple copies of segments of 
genes, whole genes, and even whole chromosomes and thus it might overlook a lot of 
important genetic variation. A third limitation that may influence the accuracy of the GCTA 
is the risk of confounding due to population stratification. This type of bias is due to the fact 
that there is a chance that genetically related people tend to be geographically proximal.
211
 
Population stratification is thought to be avoided by the use of principal components,
212
 but 
there is growing evidence that this technique might not be sufficient.
213
 Just as in the 
preceding studies, studies III and IV suffers from limitations due to possible inaccuracy of 
morbidity and mortality data. Further, they are also limited by having to use different 
estimations of GFR and not inulin or iohexol clearance. 
6.8 CLINICAL IMPLICATIONS 
Cystatin C is an easy to measure, commonly available, serum analysis already widely used in 
the clinic. Its association to atherosclerotic cardiovascular disease, whether it is causal or due 
to the proxy measure of renal dysfunction, is unambiguous. The results presented in this 
thesis expand the knowledge on the relation between cystatin C and CVD, specifically as a 
marker for environmental exposure associated to incident CVD.  We argue that our results 
support the use of cystatin C as an important biomarker sensitive for incident CVD. Thus it 
could be of value to expand its usage beyond renal medicine and include it as a tool in the 
arsenal for cardiovascular risk stratification.  
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A valid question is of course how much value will be added to risk stratification by including 
cystatin C on top of classic CVD risk markers. Two longitudinal studies have shown an 
association of an increase in cystatin C, adjusted for the classic Framingham risk factors, with 
an increased risk of CVD. 
183,214
 Still, a statistically significant correlation is not the same as a 
reclassification in terms of risk and thus may not lead to change of preventive or therapeutic 
management. Of the two studies mentioned above only the latter one found a statistically 
significant improvement of risk stratification in elderly men without cardiovascular disease 
when adding cystatin C in a multi-marker approach together with NT-proBNP, CRP and 
troponin I to the Framingham risk factors. 
 
As mentioned in the background of this thesis the majority of events will occur in individuals 
at moderate risk and thus the effect of incorporating cystatin C in this group may be marginal. 
Nevertheless, certain individuals in high risk populations may benefit from a better 
stratification as it could lead to targeted interventions that reduces their absolute risk. 
However the main focus of the papers in this thesis has not been to evaluate how big a 
plausible contribution of cystatin C as a risk marker added to present risk scoring systems 
would be. 
6.9 FUTURE PERSPECTIVES 
Through our studies we have been able to detect a solid association between cystatin C and 
atherosclerotic disease. Since large studies do not support a causal relation between cystatin C 
and CVD a continued focus on establishing evidence of causality, with the prospect of future 
interventions targeted directly at cystatin C, is probably of less interest.  
We observed that a unique environmental factor that associate to, and possibly mediate, intra-
pair discordance regarding stroke incidence was mirrored by difference in levels of cystatin C 
at baseline. This is, in accordance with results from previous studies that have shown that 
only a small fraction of stroke variance is explained by genetic overlap with renal function 
estimates. Thus an important future focus is to investigate the part of the association between 
cystatin C and ASCVD that is related to environmental factors and which is better suited as a 
target for preventive measures. 
 
Finally, studies regarding the usage of cystatin C as a predictive biomarker of different forms 
of cardiovascular disease, in different populations, are needed in order to further investigate a 
possible clinical use. Specifically studies that can show if the biomarker can improve 
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reclassification to relevant risk categories are warranted as are studies that provide cost –
benefit measures such as numbers needed to screen. Further the observed U-formed relation 
need additional investigation.  
7 CONCLUSIONS 
7.1 STUDY I 
Cystatin C concentration, adjusted for differences in eGFR, IL-6 and CRP was higher in 
PAD-patients compared to controls. Thus cystatin C may be an independent marker of 
atherosclerotic disease apart from its relation to kidney function.  
7.2 STUDY II 
Cystatin C could not predict CV events and did not improve discrimination or reclassification 
in patients with peripheral arterial disease although an interesting finding was a U-formed 
relation between cystatin C and CV events. An interpretation of this might be that cystatin C 
may reflect different activities in different stages of an ongoing atherosclerotic process. 
7.3 STUDY III 
The heritability of Cystatin C was 0.60 (0.56-0.63) and the heritability of creatinine was 0.59 
(0.56-0.62) which is higher compared to previous studies. The GCTA analysis provided 
independent evidence for the significant heritability indicated by the twin-model for all 
phenotypes. Cystatin C was weakly correlated to prevalent CVD, although more strongly 
than creatinine, and the covariation between cystatin C and CVD in males was explained by 
additive genetic components indicating that cystatin C and CVD share genetic influences.   
7.4 STUDY IV 
Variation in cystatin C was associated with incident atherosclerotic cardiovascular disease, 
independent of traditional risk factors, with a stronger association to stroke which remained 
after adjustment for genetic confounding. The finding that cystatin C is related to incident 
stroke in disease-discordant identical twins is novel and indicates that individual specific 
environmental factors that affect cystatin C also associates to stroke risk.  
7.5 OVERALL CONCLUSION 
Cystatin C is associated to atherosclerotic disease. The covariation between cystatin C and 
CVD in males indicates that cystatin C and CVD share genetic influences. Variation in 
cystatin C is associated with incident myocardial infarction and stroke independent of 
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traditional risk factors, with a stronger association to stroke. The finding that cystatin C is 
related to incident stroke in disease-discordant identical twins indicates that individual 
specific environmental factors are important. One possible explanation is that cystatin C may 
be a sensitive marker of early hypertensive end organ damage. It could be of value to expand 
the usage of cystatin C beyond renal medicine and include it as a tool in the arsenal for 
cardiovascular risk stratification. However, further research is needed. 
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